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Aims. The aim of this study was to investigate the factors associated with long-term prognosis 
and disease activity in patients with anti-neutrophil cytoplasm autoantibodies (ANCA)-
associated vasculitis (AAV). An additional aim was to define the coagulation and fibrinolysis 
profile of renal AAV patients. 
 
Methods. Four cohorts including patients with granulomatosis with polyangiitis (GPA), 
microscopic polyangiitis (MPA) and renal-limited AAV were investigated to achieve these 
aims. Long-term prognosis and relapses were assessed retrospectively in a Finnish cohort of 85 
patients with renal biopsy-proven AAV from a single centre (Study I). 
The associations between chronic nasal Staphylococcus aureus carriage (CNSAC) and 
proteinase 3 (PR3) ANCA with relapse were studied in AAV patients who participated in two 
randomised controlled trials in Europe. To define nasal CNSAC status, monthly nasal swabs 
were obtained from 200 patients with early systemic or generalised disease during the 18-month 
trials. The patient was defined as a chronic carrier of Staphylococcus aureus (S. aureus) when ≥ 
75% of at least four nasal cultures were positive for S. aureus (Study II). 
PR3-ANCA levels, which were examined via nine different enzyme-linked 
immunosorbent assays (ELISAs), were obtained monthly during the 18-month trial in 28 
patients with early systemic GPA. PR3-ANCA peaks were identified by the highest sum of 
logarithmic transformation values from all assays (Study III). 
The coagulation profile was assessed prospectively in 21 Finnish patients with renal 
AAV in the active versus the remission phase of disease and further compared with that of 40 
patients with other renal diseases. The laboratory analysis consisted of platelet count, thrombin 
time, antithrombin activities, fibrinogen, factor VIII activity (FVIIIC), von Willebrand factor 
antigen (VWF:Ag) and ristocetin cofactor activity (VWF:RCo), prothrombin fragments (F 1 + 
2), D-dimer and antiphospholipid antibodies (Study IV). 
     
Results. The 5-year and 20-year patient survival rates were 88% and 45%, respectively. Older 
age and presence of myeloperoxidase (MPO) ANCA were significantly associated with 
worsened survival. The 5-year and 20-year renal survival rates were 79% and 68%, respectively. 
Renal survival was best in a focal class and worst in the sclerotic class of AAV 
glomerulonephritis. Female sex was significantly associated with better renal survival, while a 
glomerular filtration rate < 30 ml/min and MPO-ANCA predicted worse renal survival. Relapse-
free survival at 5 years was 47% while at 20 years it was only 10%. Patients with GPA had 
higher relapse risk compared with MPA patients. (Study I). 
The frequency of CNSAC was 12% in the whole cohort. CNSAC was almost 
exclusively seen in GPA patients. In patients with generalised GPA, the association with 
CNSAC and relapse was observed. Also, in early systemic GPA, in those patients who were 
under immunosuppressive treatment, a similar trend for significant association was found (Study 
II). 
A PR3-ANCA peak corresponded to relapse. However, the PR3-ANCA peak could 
also be identified in non-relapsing patients, and large overlaps in PR3-ANCA values prevented 
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drawing a distinction between relapsing patients and non-relapsing patients. The alterations of 
immunosuppression were reflected in PR3-ANCA levels (Study III). 
F 1 + 2 and D-dimer were substantially elevated during active disease. During 
remission, their levels decreased considerably, even though D-dimer level remained above the 
reference value. FVIIIC, VWF:Ag and VFW:RCo levels were high during active AAV and 
remained elevated during remission. The load of coagulopathies during remission was 
comparable to that of patients with other renal diseases involving at least moderate renal 
impairment. No antiphospholipid antibodies were found. Among AAV patients, two 
thromboembolic complications were observed (Study IV). 
 
Conclusions. In a long-term follow-up cohort, patient and renal survival were comparable with 
recent studies showing improved prognosis as compared to earlier reports. Both patient and 
renal survival were negatively predicted by the presence of MPO-ANCA. The development of 
end-stage renal disease was more common in men. In the long run, relapses were common, 
especially in patients with GPA. One special subgroup of individuals who were more prone to 
relapse among GPA patients were those with CNSAC. PR3-ANCA levels were not only 
affected by disease activity but also reflected the level of immunosuppressive treatment. Active 
renal AAV was characterised by enhanced coagulation and fibrinolysis, which failed to 













Tausta ja tavoitteet. ANCA-vaskuliitit ovat ryhmä verrattain harvinaisia sairauksia, joita 
luonnehtivat pienten verisuonten seinämän tulehdus ja kuolio. ANCA-vaskuliitit voidaan 
jaotella kliinisen ilmiasun perusteella alaryhmiin. Granulomatoottinen polyangiitti (GPA) ja 
mikroskooppinen polyangiitti (MPA) muodostavat valtaosan tapauksista. Tautivaiheiden 
vaihtelu, eli jo rauhoittuneen taudin uusiminen, on leimallista näille taudeille. ANCA-
vaskuliittipotilailla on suurentunut riski saada veritulppa. Tämän väitöstutkimuksen 
ensisijaisena tarkoituksena oli selvittää GPA- ja MPA-potilaiden ennusteeseen ja taudin 
aktiviteettiin vaikuttavia tekijöitä. Tutkimuksessa selvitettiin myös ANCA-vaskuliittipotilaiden 
veren hyytymisprofiilia suhteessa tautiaktiviteettiin.   
 
Menetelmät. Pitkäaikaisennustetta, eli potilaiden eloonjääntiä, munuaiskorvaushoitoon 
joutumista ja taudin uusimista, tutkittiin suomalaisessa munuaistautia sairastavassa ANCA-
vaskuliittipotilaista koostuvassa aineistossa (N=85) (Tutkimus I).  
Kroonista Staphylococcus aureus-nenäkantajuutta (KSANK) ja sen yhteyttä taudin 
uusiutumis- eli relapsiriskiin tutkittiin ANCA-vaskuliittipotilailla (N=200), jotka olivat 
osallistuneet kahteen eurooppalaiseen hoitotutkimukseen. KSANK-määritelmä edellytti, että 
vähintään 75 %:a kuukausittain nenän limakalvoilta otetuista bakteeriviljelyistä oli positiivisia 
Staphylococcus aureuksen suhteen 18 kuukautta kestävän tutkimuksen aikana (Tutkimus II). 
Tautiaktiviteetin ja PR3-ANCA-vasta-ainetasojen yhteyttä tutkittiin niin ikään 
eurooppalaiseen hoitotutkimukseen osallistuneilla GPA-potilailla (N=28). Käytössä oli 
yhdeksän entsyymi-immunologista testiä ja PR3-ANCA-vasta-aineille määritettiin 
testikohtaisesti korkein taso (Tutkimus III). 
Veren hyytymisaktiviteettia tutkittiin suomalaisessa aineistossa, joka koostui 
munuaistautia sairastavista ANCA-vaskuliittipotilaista (N=21) ja muita munuaistauteja 
sairastavista verrokkipotilaista (N=40). Tutkimuksessa määritettiin verihiutalepitoisuus, plasman 
trombiiniaika, antitrombiiniaktiviteetti, fibrinogeeni, hyytymistekijä VIII:n aktiviteetti, von 
Willebrand-tekijän antigeeni ja ristosetiinikofaktorin aktiviteetti, protrombiinifragmentit, D-
dimeeri sekä fosfolipidivasta-aineet (Tutkimus IV).  
  
Tulokset. Elossaolo-osuus oli 88 % viiden vuoden kuluttua ja 45 % kahdenkymmenen vuoden 
jälkeen. Kahdenkymmenen vuoden kuluttua 32 % potilaista oli pysyvästi 
munuaiskorvaushoidossa. Potilailla, joilla oli diagnoosivaiheessa todettavissa MPO-ANCA-
vasta-aineita, oli heikompi ennuste sekä eloonjäännin että munuaistoiminnan suhteen. Miehet 
päätyivät naisia useammin munuaiskorvaushoitoon. Vain 10 % potilaista vältti taudin uusimisen 
kahdenkymmenen vuoden seurannassa ja relapsi oli tavallisempi GPA-potilailla (Tutkimus I). 
Krooninen Staphylococcus aureus nenäkantajuus todettiin 12 %:lla potilaista ja 
valtaosa heistä oli GPA-potilaita. Nenäkantajilla oli suurempi relapsi- eli taudin uusimisriski 
(Tutkimus II). 
Relapoivilla potilailla (N=16) PR3-ANCA-vasta-ainetason huippu osui taudin 
relapsiajankohtaan. Kuitenkin myös niillä potilailla, joilla vaskuliitti pysyi rauhallisena, todettiin 
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samankaltainen PR3-ANCA-vasta-ainetasojen nousu immunosupressiivisen lääkityksen 
vähentyessä (Tutkimus III). 
Diagnoosivaiheen ANCA-vaskuliittia sairastavilla todettiin protromboottinen tila. 
Erityisesti trombiinin muodostus ja kohonnut D-dimeeri vallitsivat aktiivisessa taudissa. Taudin 
rauhoituttua hyytymisalttius väheni, mutta edelleen erityisesti hyytymistekijä VIII aktiviteetti oli 
koholla. Seuranta-aikana kahdella vaskuliittipotilaalla todettiin veritulppa (Tutkimus IV).   
 
Johtopäätökset. Suomalaisten ANCA-vaskuliittipotilaiden pitkäaikaisseurannassa voitiin todeta 
viimeaikaisiin kansainvälisiin tuloksiin vertautuva, aiempiin vuosikymmeniin nähden 
parantunut ennuste sekä kuolleisuuden että munuaistoiminnan suhteen. Potilailla, joilla oli 
diagnoosivaiheessa todettavissa MPO-ANCA-vasta-aineita, oli heikompi ennuste sekä 
eloonjäännin että munuaistoiminnan suhteen. Miehet päätyivät naisia useammin 
munuaiskorvaushoitoon. Taudin uusiminen oli pitkäaikaisseurannassa yleistä erityisesti GPA-
potilailla. Kroonisen Staphylococcus aureus-nenäkantajuuden perusteella voitiin tunnistaa GPA-
potilaat, jotka olivat alttiita saamaan tautirelapsin. PR3-ANCA-vasta-ainetasot heijastivat 
tautiaktiviteetin lisäksi myös immunosupressiivisen lääkityksen kuormaa. Aktiivisessa, 
diagnoosivaiheen ANCA-vaskuliitissa veren hyytymisaktiviteetti oli korostunutta eikä se 







Granulomatosis with polyangiitis (GPA), microscopic polyangiitis (MPA) and eosinophilic 
granulomatosis with polyangiitis (EGPA) are small-vessel vasculitides characterised by anti-
neutrophil cytoplasm autoantibodies (ANCA). Together, they form an entity called ANCA-
associated vasculitis (AAV). 
Vasculitis refers to an inflammatory process in the blood vessel walls. In AAV, 
vessels of small or medium size are affected, leading to symptoms and signs of ischaemia or 
haemorrhage in the target organ. Fundamentally, any organ or even many organs of the body 
can be affected simultaneously, or the disease may be localised. Rapidly progressive 
glomerulonephritis (GN), one of the most hazardous conditions in nephrology, is often caused 
by AAV. Another life-threatening manifestation of AAV is vasculitis of the lung capillaries 
leading to alveolar haemorrhage. Due to the variable presentation of the disease and its rather 
low incidence, the diagnosis may be difficult and delayed. Thanks to effective 
immunosuppressive medication and decreased diagnostic delay, the prognosis of AAV patients 
has improved dramatically over the last decades. Today, AAV is a chronic disease commonly 
associated with relapse. Depending on the disease state and diagnostic subgroup, renal 
manifestation is common, and the need for permanent dialysis is frequent in patients with AAV. 
End-stage renal disease (ESRD) is not only a tragedy for an individual but also shortens 
patients’ lifespan.  
The first purpose of this study was to describe the long-term survival of renal patients 
with biopsy-proven AAV. The potential of a recently launched classification schema for AAV 
glomerulonephritis (AAGN) to act as a predictor of survival was validated retrospectively [1].  
An additional goal of this study concerned relapse. In cases of relapsing disease, 
determining the factors related to disease activity is remarkably important in identifying those 
patients who are in need of extended immunosuppressive medication. Previously, the role of 
infectious agents, and Staphylococcus aureus (S. aureus) in particular, as disease triggers has 
been suggested [2-4]. Additionally, ANCAs play an undisputed role in the diagnosis of AAV. 
However, their role as a marker of disease activity has been a subject of controversy since their 
recognition. In two randomised controlled trials (RCTs) conducted by the European Vasculitis 
(EUVAS) Study Group in newly diagnosed AAV patients, the associations between chronic 
nasal S. aureus carriage (CNSAC) and proteinase 3 (PR3) ANCA levels and relapse were 
defined. 
During the disease course, patients accumulate organ damage due to disease activity 
and other complications, such as infections and malignancies. An increased risk of 
thromboembolic events in AAV patients was recognised a decade ago [5, 6]. As a third 
component of this study, the activation of coagulation and fibrinolysis was addressed in a 
prospective cohort of newly diagnosed renal AAV patients during the acute and remission 
phases of the disease. 
Patients with EGPA, the rarest form of AAV, were not included in the original publications of 
this study. That is, this thesis focuses on GPA and MPA, including AAV patients with renal 
limited vasculitis (RLV). 
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2  REVIEW OF THE LITERATURE 
2.1. Pioneers and historic milestones in vasculitis  
 
Historically, the first description of systemic vasculitis concerned polyarteritis (periarteritis) 
nodosa and was made by Adolf Kussmaul and Rudolf Robert Maier in 1866 [7]. In 1939, 
Friedrich Wegener published four cases “about a peculiar rhinogenic granulomatosis with 
marked involvement of the arterial system and kidneys”, describing the classical triad of 
symptoms that carried his name for over 70 years (Wegener’s granulomatosis) [8]. However, as 
early as 1931, Heinz Klinger reported a similar case, assuming that it was a “borderline variant 
of periarteritis nodosa” [9]. In 1951, Jacob Churg and Lotte Strauss presented allergic 
granulomatosis (Churg-Strauss syndrome) [10]. In 1985, Fokko van der Woude et al. discovered 
ANCAs in the blood of GPA (Wegener’s) patients, and the era of ANCA vasculitides was 
launched [11]. 
 
2.2. Classification of AAV  
 
The classification of vasculitides is based on the similar phenotypes observed in groups of 
patients and the size of the affected vessels. Since 1990, the American College of Rheumatology 
(ACR) classification criteria have mainly aimed to ensure uniformity of diagnosis for purposes 
of epidemiological studies [12]. In 1994, the Chapel Hill Consensus Conference (CHCC1994) 
nomenclature provided definitions for vasculitis based on the size of the affected vessels [13]. In 
the CHCC1994, MPA was detached from classical polyarteritis nodosa and came to be 
considered a separate disease. It was also distinguished from Wegener’s granulomatosis and 
Churg-Strauss syndrome by the absence of granuloma. The importance of ANCA serology in 
diagnosis was noted but not included. The European Medicines Agency (EMA) algorithm (also 
known as Watts’ algorithm), which combines the ACR and CHCC classifications, attempted to 
further classify patients by using surrogates for vasculitis and granuloma when histological 
biopsy was not possible [14]. 
In 2012, the CHCC nomenclature was revised (CHCC2012) [15]. In this version, the 
major feature was the phasing out of eponyms whenever pathophysiological knowledge allowed 
to propose descriptive names. Accordingly, Wegener’s granulomatosis was renamed GPA, and 
Churg-Strauss syndrome was renamed EGPA. Together with MPA, they were combined in the 
form of AAV and placed within the small-vessel vasculitis group. The definitions of AAV 
subsets provided in CHCC2012 are given in Table 1. 
An alternative perspective on diagnosis is the use of ANCA serology to classify 
patients. Instead of GPA and MPA, it is thus possible to use PR3-ANCA-positive disease or 
myeloperoxidase (MPO) ANCA-positive disease. A combination of both phenotype and 
ANCA-specificity was also suggested by CHCC2012 (for example, PR3-ANCA positive GPA) 
[15]. Indeed, grouping patients by ANCA specificity is increasingly discussed because serology, 
more so than phenotype, correlates with genetics, epidemiology and prognosis (as discussed 
later in this study). 
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To date, however, no diagnostic criteria are available, and the results of a large 
multinational study are awaited; the ongoing Diagnostic and Classification Criteria in Vasculitis 
study aims to develop diagnostic criteria and update the classification criteria for vasculitis [16]. 
 
Table 1. Definitions of AAV according to CHCC2012.  
 
MPA Predominantly small-vessel necrotising vasculitis  
Necrotising glomerulonephritis is very common 
Pulmonary capillaritis often occurs 
Granulomatous inflammation is absent 
GPA Granulomatous inflammation usually involving the upper and lower respiratory tract 
Predominantly small-vessel necrotising vasculitis  
Necrotising glomerulonephritis is common 
EGPA Eosinophil-rich granulomatous inflammation often involving the respiratory tract 
Predominantly small-vessel necrotising vasculitis  
Asthma and eosinophilia 




From the 1980s to the 1990s, increasing incidences of AAV, particularly of GPA, were reported 
in several studies [17-19]. This increase in incidence was most likely due to better awareness of 
the disease by physicians due to the introduction of ANCA testing into clinical practice in the 
early 1990s [19]. Since the early 2000s, studies have suggested a stable annual incidence of 
AAV in Europe of 20/million inhabitants [20, 21]. The incidence of GPA is suggested to be 
higher than that of MPA in Northern Europe while MPA predominates in Southern Europe [20, 
22, 23]. However, this North-South gradient is not confirmed in all cohorts [21, 24]. In Finland, 
the incidence of GPA in the late 1990s was 9.3/million [19]. 
Both GPA and MPA can occur at any age, but they are most often diagnosed after 
patients reach the age of 55 years [19, 21]. The incidence peaks after 65 and seems to be higher 
for MPA than GPA [19, 21]. In adults, both sexes are equally affected by AAV. However, in 
cases of GPA, the male-to-female ratio is 1.3–1.6, while in MPA, the opposite male-female 
ratio, 0.5–0.9, is reported [17, 25, 26]. 
The point prevalences of AAV in the 2000s in Europe are 146–160/million for GPA 
and 63-94/million for MPA [26, 27]. In Japan and China, on the other hand, MPA- and MPO-
associated vasculitis are much more common than GPA [26, 27]. 
 
2.4. ANCA detection 
 
ANCAs are autoantibodies directed toward multiple intracellular antigens in neutrophils and 
monocytes. Such neutrophil-specific autoantibodies (called anti-leukocyte factors at that time) 
were originally detected in the late 1950s via an indirect immunofluorescence (IIF) technique in 
patients with leucopenia and various autoimmune diseases [28]. These autoantibodies were first 
related to vasculitis patients with segmental necrotising GN in the early 1980s [29]. Soon after, 
antibodies revealing a cytoplasmic fluorescence pattern (referred to as C-ANCA) were detected 
16 
 
via IIF on ethanol-fixed neutrophils in patients with GPA [11]. A few years later, an alternative 
fluorescence pattern, perinuclear ANCA (P-ANCA), was recognised in vasculitis patients [30, 
31]. 
The major antigen of C-ANCA is PR3, which is a 29-kDa serine protease of myeloid 
azurophilic granules consisting of 229 amino acids. PR3 can degrade phagocytosed bacteria and 
other extracellular material and cause tissue damage [32]. The main antigen for P-ANCA in 
AAV is MPO. Highly cationic MPO, with a molecular weight of 140 kDa, is an enzyme with 
bactericidal properties in neutrophils and monocytes that acts by catalysing the peroxidation of 
chloride into hypochlorite [32]. ANCAs (most often P-ANCA or atypical ANCA) may also be 
detected in patients with a variety of autoimmune, inflammatory and infectious diseases and in 
cases of drug exposure, which typically involves other antigens, such as lactoferrin, elastase, 
cathepsin G, bactericidal permeability-increasing protein and others. Thus, P-ANCA is not 
specific to AAV and must therefore be confirmed by determining the specific antigen for AAV 
(that is, PR3 or MPO) via an enzyme-linked immunosorbent assay (ELISA). Recently, 
circulating autoantibodies against MPO and PR3 have been found in asymptomatic individuals 
and designated as “natural” or non-pathogenic autoantibodies [33]. More than 20 different MPO 
epitopes bound by MPO-ANCA have been identified, and epitope specificities of healthy 
individuals were different from those recognised in patients with active disease [34]. 
Furthermore, it was suggested that a reaction against the natural epitope may become 
generalised from non-pathogenic to pathogenic epitopes through a process of epitope spreading 
when the disease develops [34]. 
Direct ELISA testing was originally performed by direct enzyme-linked assays using 
purified, solid-phase PR3 and MPO antigens bound to the wells of high-binding microplates, as 
illustrated in Figure 1. The second-generation assay, so-called capture ELISA, uses secondary 
antibodies to capture PR3 or MPO on the plate [35] (Figure 1). The capture method reduces the 
potential covering of epitopes by the plate and consolidates the conformation of epitopes, 
leading to better recognition of the antigen by the autoantibodies. This allowed for better 
sensitivity in PR3 detection [36, 37]. In the third-generation assays for ANCA detection, so-
called anchor ELISAs or high-sensitivity ELISAs, the antigen is immobilised on the plate by a 
bridging molecule (Figure 1). This allows preserving the epitopes for antibody binding, resulting 
in better diagnostic performance as compared to direct ELISAs and some capture ELISAs [38]. 
However, in other comparisons, the second (capture) and third (high-sensitivity) generation 
PR3-ANCA assays have performed equally well as conventional direct ELISAs [39, 40]. Most 
commonly, anchor assays are still used in the detection of PR3-ANCA. Another technology for 
ANCA ELISA uses recombinant autoantigens instead of human antigens to further improve 
antibody binding [41]. In addition, several new developments in ANCA-specificity detection are 
available: fluorescent-enzyme immunoassays, addressable laser bead immunoassays, 
chemiluminescent immunoassays and dot or line immunoassays [41]. Because the interpretation 
of conventional IIF is highly subjective and time-consuming, automated systems that can 
perform computer-aided analysis of IIF images using pattern-recognition algorithms are 
promising techniques [42]. 
A consensus statement from 1999 holds that positive IIF results must be confirmed 
with antigen-specific tests for PR3-ANCA and MPO-ANCA [43]. However, this two-phase 
procedure has been questioned during the last years. In 2016, a European multicentre study 
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confirmed that due to the equal or even improved diagnostic performance (measured by the area 
under the receiver operating characteristics curve) of novel PR3- and MPO-ANCA 
immunoassays (including first-, second- and third-generation assays) as compared to IIF, 
double-checking with IIF and antigen-specific immunoassays will no longer be necessary [44]. 
Finally, based on the European multicentre study [44], the revised international consensus 
statement on testing ANCAs in GPA and MPA concluded that high-quality immunoassays for 
PR3- and MPO-ANCA should be used as a primary screening method for patients suspected of 




Figure 1. ANCA detection by antigen-specific assays.  





The pathogenesis of AAV remains incompletely understood. However, intensive research 
during the last decades has provided increasing knowledge about this multifactorial process 
involving genetics and environmental triggers, combined with both the innate and adaptive 
immune systems. The potential factors that may contribute to the immune mechanisms 
underlying interrupted self-tolerance and the induction of autoimmunity as well as the 
anticipated main mechanism leading to vascular damage are discussed below. 
 
2.5.1. Genetic associations 
 
Even though the risk of GPA in first-degree relatives is low, family clusters of GPA and MPA 
have been described, suggesting a genetic influence on the pathogenesis of AAV [46, 47]. AAV 
rarely occurs in African Americans. However, the HLA-DRB1*15 allele was over-represented 
(odds ratio 73) in African American patients with PR3-ANCA-positive disease as compared to 
community-based controls, and the frequency of this allele was clearly higher than in 
Caucasians with PR3-ANCA positive disease [48]. Two recently published genome-wide 
association studies have confirmed genetic associations with AAV and concluded that these are 
different from those observed with GPA and MPA [49, 50]. GPA was associated with HLA-DP, 
SERPINA 1 (encoding for serine protease inhibitor alpha 1 antitrypsin) and PRTN3 (encoding 
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PR3), and MPA was associated with HLA-DQ polymorphisms. Moreover, these genetic 
associations were stronger for ANCA specificity than for AAV clinical phenotypes [49].  
 
2.5.2. Infections, with a special emphasis on S. aureus 
 
The role of microbial infection as a cause of granulomatous disease in GPA was suggested by 
Wegener himself in his original article [8]. The most convincing evidence of microbiological 
associations in the aetiology of AAV is derived from S. aureus. The role of S. aureus as a 
potential trigger of disease activity in GPA was suggested by several groups during the early 
1980s [2, 3]. High CNSAC percentages, up to 60–72%, have been reported in cases of GPA [4, 
51, 52], whereas in the normal population, 20–30% of individuals are chronic carriers [53, 54]. 
In cases of GPA, a seven-fold relapse risk was reported in patients with CNSAC by Stegeman et 
al. [4]; others have also reported increased risks, but not to this degree [51, 52, 55]. GPA 
patients have been shown to have epithelial nasal barrier dysfunction due to their altered 
antimicrobial peptide response and dysregulated cytokine expression, which could facilitate S. 
aureus colonisation and contribute to disease activity [56, 57]. 
Staphylococcal super-antigens, such as toxic shock syndrome toxin-1 (TSST-1), are 
extremely potent T-cell activators that lead to polyclonal T-cell proliferation and a massive 
release of cytokines [58]. Indeed, TSST-1-positive S. aureus was especially implicated in an 
increased risk of relapse among GPA patients, suggesting that staphylococcal super-antigens 
may mediate S. aureus pathogenicity [59]. However, recent data from studies on humoral 
immune responses and genetic studies of S. aureus in GPA patients do not support the 
pathogenic role of TSST-1 or other staphylococcal super-antigens in GPA [60, 61]. 
Surprisingly, sera from GPA patients contained lower anti-staphylococcal IgG levels than sera 
from healthy controls, even though the total immunoglobulin G (IgG) levels were not different 
[60]. In the same study, no particular S. aureus genotype in nasal isolates taken from GPA 
patients was found to be different from that of healthy controls, suggesting that GPA patients 
may have poorer humoral immune protection against S. aureus than healthy persons. Low levels 
of anti-staphylococcal antibodies are also found in MPO-ANCA patients; these levels are 
comparable to those seen in PR3-ANCA patients [61]. As shown via a DNA microarray-based 
approach, several genetic loci of S. aureus are associated with either MPO- or PR3-ANCA 
AAV; a gene encoding leucocidin, a pore-forming toxin, was detected in S. aureus nasal isolates 
taken from PR3-ANCA patients, implying the potential role of this virulence factor in the 
survival of S. aureus in the nasal mucosa [61]. 
The theory of molecular mimicry has been postulated to interpret the relationship 
between S. aureus and PR3-ANCA formation: the genetic sequences of antisense regions 
complementary to PR3 (cPR3) are found in S. aureus, implying that cPR3 could serve as 
antigenic target for PR3-ANCA formation through anti-idiotypic antibodies in GPA [62, 63]. 
Nevertheless, anti-cPR3-reactivity was not increased in PR3-ANCA-associated vasculitis 
patients [64]. The theory of molecular mimicry is implicated in another context related to the 
infection-associated background of AAV as well. Kain et al. found antibodies against lysosomal 
membrane-associated protein-2 (LAMP-2) in individuals with active pauci-immune focal 
necrotic GN [65]. LAMP-2 shares sequence homology with FimH (a gram-negative bacterial 
adhesion molecule), and LAMP-2-ab is capable of cross-reacting with FimH [65]. Furthermore, 
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antibodies to human LAMP-2 can induce focal necrotic GN when injected into rats. However, 
these observations could not be reproduced by another group [66]. 
 
2.5.3. Environmental factors and drugs 
 
Environmental exposures have also been incriminated as triggers of vasculitis: silica, as a risk 
determinant, is linked to AAV in several case-control studies [67-69]. A recent meta-analysis 
found an odds ratio (OR) of 2.56 for the association between silica exposure and the risk of 
developing AAV [70]. High levels of silica dust released into air during the 1995 earthquake in 
Kobe, Japan, and the subsequent increase of MPO-ANCA-associated vasculitis suggest a causal 
relationship [71].  
Farming at the year of diagnosis was associated to GPA (OR 2.7), and this risk was 
particularly associated with exposure to livestock [69]. However, a case-control study of GPA 
from Sweden found no occupational risk associations [72]. In addition, various drugs, such as 
propylthiouracil, hydralazine, minocycline, sulfasalazine, penicillamine, allopurinol and 
rifampicin, are associated with AAV [73, 74]. These drugs may induce ANCA seroconversion, 
mainly against MPO but also against other antigens (elastase, lactoferrin). In most cases, no 
treatment other than discontinuing the drug is needed to cure the vasculitis.  
 
2.5.4. The anticipated main mechanism of ANCA-induced neutrophil activation and 
endothelial damage 
 
Neutrophils are believed to be the key players orchestrating the multiple steps leading to tissue 
damage in AAV. Neutrophil activation by ANCA seems to be the primary event. In vitro studies 
have shown that MPO and PR3-ANCA are able to activate neutrophils that have been pre-
activated through a process called priming by pro-inflammatory stimuli, such as tumour necrosis 
factor-α, bacterial lipopolysaccharide, interleukin 18 or complement component 5a (C5a) [75-
78]. In resting neutrophils, PR3 and MPO are located in the lysosomal compartment and thus 
inaccessible to antibody binding. However, priming causes the translocation of ANCA antigens 
to the cell surface and leads to a microenvironment in which interactions with ANCAs may take 
place [79]. The engagement of the Fc receptor on neutrophils with ANCA-antigen 
immunocomplexes and the binding of the F(ab’)2 of ANCA to the antigens expressed on the 
neutrophil surface complete neutrophil activation [79-82]. These ANCA-activated neutrophils 
adhere and transmigrate through the vessel wall and undergo respiratory burst with the release 
of reactive oxygen species and lytic enzymes, causing apoptosis, NETosis (see later) and the 
necrosis of the neutrophils and adjacent vessel wall [75, 83, 84]. Ultimately, inflammatory 
endothelial cell damage as a result of endothelium-neutrophil interaction leads to a loss of anti-
thrombogenic activity of endothelium, resulting in haemorrhage and the release of plasma 
proteins, including coagulation factors and tissue factor, leading to fibrin formation [79, 85].  
Increasing evidence suggests that an alternative complement pathway plays an 
important role in the pathogenesis of AAV. The generation of C5a, which is a potent 
chemoattractant for neutrophils and capable of priming them, was also found in the supernatants 
of ANCA-activated neutrophils [78]. Thus, the interaction between C5a and the C5a receptor 
can result in a pro-inflammatory amplification loop. In a mouse model, researchers found that 
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the ablation of complement component C5 and the depletion of complement component C3 
prevented disease after the transfer of anti-MPO IgG [86]. Later, observations of patients have 
supported the role of the activation of the alternative complement pathway in the pathogenesis 
of AAV [87, 88]. Furthermore, the pharmacological blockade of the C5a receptor by oral C5a 
receptor antagonist protected transgenic mice from AAV [89].  
Yet another novelty suggested in the pathogenesis of AAV is NETosis, as mentioned 
above. As a defensive strategy against pathogens, activated neutrophils have been shown to 
release webs of decondensed fibres of chromatin called neutrophil extracellular traps (NETs) 
into the extracellular space [90]. In the kidneys of AAV patients, NETs containing PR3 and 
MPO have been found, indicating that NETosis could be one of the mechanisms via which these 
autoantigens are presented to the immune system [91]. This simplified sequence of pathogenic 




Figure 2. Supposed sequence of pathogenetic events in AAV.  






Excessive NETosis also seems contribute to thrombosis in AAV. In a case study, 
NETs were identified in a thrombus and glomerular crescents from a MPA patient. In this 
patient, the number of NETs in this thrombus was also higher compared to those in other 
thrombi unrelated to MPA [92]. Furthermore, in active AAV, neutrophils activated by 
inflammatory mediators and ANCA induced the release of tissue-factor-expressing NETs and 
microparticles [93]. In vitro, neutrophil-derived microparticles can promote the generation of 
thrombin [94]. This was also shown in vivo in children with active vasculitis complicated by 
venous thromboembolic events (VTE) [95]. 
 
2.6. Clinical characteristics and diagnosis 
  
2.6.1  Symptoms and findings 
 
Suspicion of AAV is based on a combination of symptoms and clinical findings, in addition to 
abnormal results on blood and urinary tests.  A typical patient presents with general symptoms 
such as fever, weight loss and arthralgia, which may have continued for months. Non-specific 
haematological signs of acute inflammation, such as elevated C-reactive protein (CRP), 
hypersedimentation, anaemia and thrombocytosis, are commonly observed in the acute phase of 
generalised AAV.   
Upper respiratory tract disease is particularly common in GPA, including the 
involvement of vessels supplying the cartilage of the septum, which may lead to septal 
perforation and saddle nose deformation. In MPA, ear, nose and throat (ENT) involvement may 
occur, but without granuloma and destruction. The inflammation of the trachea, often in the 
subglottic region, is also typical of GPA. 
Lung involvement is common in AAV. The symptoms may vary from cough to 
haemoptysis, and radiograph findings may reveal nodules, pulmonary infiltrates and hilar 
adenopathy. 
Renal involvement is frequent in GPA and MPA. In urine, unspecific findings, such as 
microscopic haematuria and proteinuria, which is usually non-nephrotic (i.e. <3 g/day), can be 
detected in case of active renal AAV. Renal insufficiency, and even rapidly progressive GN, is 
commonly seen in AAV.   
The clinical picture of AAV varies, and the most common organ-specific 
presentations are shown in the Table 2, which is organised according to the Birmingham 
vasculitis activity score (BVAS) [96]. BVAS summarises AAV symptoms and findings into 
nine different organ systems, giving points for each item attributable to active vasculitis 
(maximum total score of 63). BVAS serves as a valuable aid when evaluating disease activity in 
AAV patients, although some training is needed to apply this instrument correctly. 
Occasionally, AAV is limited to one organ group: RLV is often regarded as a form of 
MPA. GPA, in the diagnostic phase, may be limited to the ENT, although the disease tends to 








A definite diagnosis is based on a typical histologic finding obtained from a biopsy of the 
affected organ. The biopsy of purpuric skin lesions reveals leucocytoclastic vasculitis, although 
this is a non-specific finding. Nasal biopsies are rarely diagnostic, whereas open lung biopsies 
have a high sensitivity, but because this is an invasive procedure, its use is limited in clinical 
practice. Renal biopsy is the main diagnostic approach in nephrology, as well as the most 
important tool for establishing a diagnosis in patients who have signs of renal involvement. 
However, a biopsy is not always possible or safe (for example, in a patient with only one 
functioning kidney), in which case diagnosis must be based on the typical findings, ANCA-
positivity and the exclusion of other aetiologies.  
The diagnosis is supported by positive ANCA testing. MPA patients are 
predominantly P and/or MPO-ANCA-positive (61.4–90.4%), whereas GPA patients are often C 
and/or PR3-ANCA-positive (73.9–78.5%) [97, 98]. However, even with modern ANCA assays, 
up to 16% of MPA and GPA patients proved ANCA-negative at diagnosis [44]. ANCA-negative 
patients often have limited GPA.   
 
Table 2. Major clinical characteristics and their occurrence in microscopic polyangiitis and 
granulomatosis with polyangiitis. 
 
Clinical manifestations MPA GPA 
Constitutional symptoms 
fever, malaise, myalgia, arthralgia, weight loss 
+++ +++ 
Ear, nose and throat involvement  
purulent/bloody nasal discharge, crusting rhinitis, sinusitis,  





hoarseness, haemoptysis/alveolar haemorrhage, pneumonia,  









purpura, ulceration, livedo reticularis 
++ ++ 
Eye involvement 




mononeuritis multiplex, sensory peripheral neuropathy, stroke, 





pericarditis, cardiomyopathy, ischemia, congestive heart failure 
+ + 
Gastrointestinal involvement 
ischaemia, bloody diarrhoea, peritonitis 
+ + 
MPA = microscopic polyangiitis; GPA = granulomatosis with polyangiitis; + = rare (occurrence <15% of patients); 
++ = common (in 15–50%); +++ = frequent; (in >50%)   
Adapted from Mahr A, Katsahian S, Varet H et al. Ann Rheum Dis 2013; 72(6):1003-1010 (including 277 MPA 
and 396 GPA patients) and Solans-Laqué R, Fraile G, Rodriguez-Carballeira M et al. Medicine (Baltimore) 2017; 
96:e6083 (including 167 MPA and 184 GPA patients).  
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2.6.3.  Renal histology  
 
Fibrinoid necrosis in the vascular wall is a hallmark of vasculitis. The presence of fibrinoid 
necrosis and/or extracapillary proliferation upon light microscopy, combined with the absence 
(or weak staining) of immune deposits upon immunofluorescence microscopy, is called pauci-
immune necrotising glomerulonephritis, which enables the histopathological diagnosis of renal 
AAV. Glomerular extracapillary proliferation refers to cell proliferation into the urinary space of 
Bowman’s capsule, giving the appearance of a crescent. Although a crescentic lesion per se is 
nonspecific and observed in a few other types of GN, pauci-immune GN is the most common 
cause of crescentic GN [99]. A cellular crescent is a sign of active disease whereas a 
fibrocellular crescent refers to chronicity, and both can be found in the same biopsy. The typical 
findings of renal histology upon light microscopy are illustrated in Figure 3. 
 
   
 
Figure 3. A normal glomerulus surrounded by normal interstitial tissue (A). A cellular crescent 
with fibrinoid necrosis (arrow) (B). A fibrocellular crescent (arrow) with fibrosis and some 
cellularity left (C). A globally sclerotic glomerulus (D). 
 
Vasculitis of the arteries and arterioles is quite seldom seen (~25%) in renal biopsies 
of AAV patients. Renal granulomas are rare and present in 5% of patients with GPA [100]. 
Patients with MPA and especially those positive for MPO-ANCA often have advanced injury in   
renal histology (glomerulosclerosis, interstitial fibrosis, tubular atrophy and arteriosclerosis) as 
compared to GPA or PR3-ANCA-positive patients [101].  
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In 2010, a histopathological classification schema for AAGN was introduced [1]. This 
classification schema is based on four classes–focal, crescentic, sclerotic and mixed–depending 
on the predominance of the affected glomeruli upon light microscopy, as shown in Table 3.  
 
Table 3. Classification of AAGN. 
 
Class Distribution of glomeruli 
Focal ≥ 50% normal glomeruli 
Crescentic ≥ 50% glomerular with cellular crescents 
Sclerotic ≥ 50% globally sclerotic glomeruli 
Mixed < 50% normal, < 50% crescentic, <50% globally sclerotic glomeruli 
Adapted from Berden AE, Ferrario F, Hagen EC et al. J Am Soc Nephorol 2010; 21(10):1628-1636. 
 
2.7. Treatment of AAV 
 
To control disease activity and avoid organ damage, treatment should be begun promptly after 
diagnosis. Occasionally, a patient’s condition worsens within a few days (for example, in the 
case of rapidly progressive GN or pulmonary haemorrhage), and treatment cannot be delayed 
until a definite diagnosis based on a biopsy of the affected organ is available. According to 
criteria used in EUVAS trials, the disease state is classified as localised (no  systemic features 
outside ENT or lung, no constitutional symptoms), early systemic (absence of disease features 
that would threaten the organ’s function, constitutional symptoms present), generalised 
(systemic disease, threatened vital organ function) or severe (organ failure present or the 
patient’s life threatened) [102]. However, disease state can change over time, and patients with 
early systematic disease may develop severe manifestations, in which case they should be 
treated accordingly [103]. The treatment of AAV is comprised of two phases: induction 
treatment to achieve remission and, when remission is achieved, maintenance treatment. In 
addition, relapses must be treated. 
 
2.7.1.  Induction of remission  
 
For over 40 years, the induction treatment of severe AAV has been based on glucocorticoids 
(GC) and cyclophosphamide (CYC) [104]. This combination of oral CYC and GC induces 
remission in 90% of patients within 3–6 months [105]. GC can be started with one to three 
intravenous (iv) pulses of methylprednisolone in cases of generalised disease, followed by oral 
predniso(lo)ne. Alongside GC, CYC can be administrated orally or iv with a similar remission 
induction success rate [106]. The iv pulse strategy, as compared to the oral, cuts down the 
cumulative dose of CYC, thus reducing the drawbacks associated with the medication 
(cytopenia, infection and infertility). Although this approach achieves more relapses, there is no 
difference in survival or kidney function in the long run [107]. To avoid the occurrence of 
uroepithelial toxicities of CYC, 2-mercaptoethanesulfonate sodium, either iv or orally, is 
recommended for patients receiving CYC [108]. A daily dose of between 7.5 and 10 mg of 
prednisolone (or equivalent) after 3 months was recently recommended [108]. 
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As an induction medication, rituximab (RTX) has been shown to be equally effective 
as CYC in two RCTs (the RAVE and RITUXVAS trials) [109, 110]. Notably, patients with 
severe kidney disease were scarce in these studies. In the RAVE trial, patients with creatinine ≥ 
4 mg/dl (corresponding to ~350 µmol/l) were excluded, whereas in the RITUXVAS trial, 
patients with low glomerular filtration rates (GFR) were allowed, while there were fewer than 
ten patients on dialysis [109, 110]. In a small retrospective study of AAV patients with severe 
renal disease (median GFR 13 ml/min), however, no differences in remission, renal recovery, 
ESRD or death were observed in RTX- and GC-treated patients with or without concomitant 
CYC [111]. In sub-analyses of the RAVE trial, RTX was more effective than CYC in patients 
experiencing relapse and also in PR3-ANCA-positive patients [109, 112]. Thus, RTX can be 
recommended for relapsing patients, those with plans for pregnancy and those who have already 
received large cumulative doses of CYC.  
Prophylactic doses of trimethoprim/sulfamethoxazole (T/S) against Pneumocystis 
jirovecii pneumonia is recommended in patients treated with CYC, as well as those receiving 
RTX [108]. 
 The addition of plasma exchange (PEX) is recommended for patients with rapidly 
deteriorating renal function and advanced kidney failure (creatinine > 500 µmol/l), as well as 
those suffering from pulmonary haemorrhage [108]. Thus far, the evidence regarding PEX is 
restricted to the MEPEX trial, which showed that in comparison to iv GC pulses, the risk of 
progression to ESRD at 12 months was lower with PEX [113]. The multinational PEXIVAS 
trial included 700 GPA and MPA patients with renal (GFR < 50ml/min) or severe pulmonary 
disease [114]. Patients were randomised to receive PEX or no PEX, and to receive standard or 
reduced oral GC dosing. All patients received immunosuppression with either CYC or RTX. 
The preliminary results of the PEXIVAS trial concluded, however, that all-cause mortality and 
the risk of ESRD were not lower in patients treated with PEX (a lecture by Michael Walsh on 
25th of May 2018 at the 55th Meeting of the European Renal Association – European Dialysis 
and Transplant Association). In addition, the preliminary results of PEXIVAS concluded that 
the reduced dose of GC (i.e. < 60% of the cumulative oral dose of a standard regimen by six 
months) was non-inferior to a standard dose and resulted in fewer serious infections. 
To avoid CYC toxicity in cases of non-severe AAV, alternative treatments have been 
tested. In the NORAM trial (A Randomised Trial of Cyclophosphamide Versus Methotrexate 
for Induction of Remission in Early Systemic Antineutrophil Cytoplasmic Antibody-Associated 
Vasculitis), methotrexate (MTX) was compared with oral CYC and found to be equally 
successful in inducing remission among patients with early systematic disease, although this 
came at the expense of a higher early relapse rate with MTX [115]. In the follow-up of the 
NORAM trial, which lasted a median of 6 years, patients in the MTX group received 
immunosuppressive medications for longer periods of time than those in the CYC group, with 
no difference in the occurrence of major adverse events (ESRD, cancer or serious infections), 
but again, there was a tendency toward shorter relapse-free survival with MTX [116]. According 
to evidence from the two small RCTs comparing mycophenolate mofetil (MMF) with CYC 
mainly in terms of their effects on MPA patients, MMF and GC can be used as an induction 





2.7.2. Maintenance of remission 
 
Remission is often defined by the absence of vasculitis disease activity, which in renal AAV is 
determined as the absence of microscopic haematuria and stable or improved proteinuria and 
GFR. Remission treatment with a lower-level immunosuppression, often including GC, is used 
to avoid relapses. However, in dialysis-dependent patients with no extrarenal disease activity, 
immunosuppression should be terminated after 4 months [119].  
Azathioprine (AZA) has been shown to be equally effective as oral CYC in remission 
maintenance after oral CYC-based induction, as shown in the CYCAZAREM trial (A 
Randomised Trial of Maintenance Therapy for Vasculitis Associated with Antineutrophil 
Cytoplasmic Autoantibodies) [105]. More recently, in the MAINRITSAN trial, RTX was found 
to prevent major relapses better than AZA after CYC-induced remission during a 2-year follow-
up [120]. Furthermore, in the 60-month follow-up of the MAINTRISAN trial, the rate of 
sustained remission remained superior on RTX-based maintenance regimen [121]. MTX 
performed as well as AZA in terms of maintaining remission and may be an alternative to AZA 
in patients intolerant of this drug who have mild or no renal disease [122].  
Leflunomide could be a more effective alternative to MTX in terms of remission 
maintenance, as shown in German GPA patients; however, more adverse events occurred in the 
leflunomide group [123]. Recently, the results of an RCT performed with AAV patients and 
comparing MTX to oral CYC after induction treatment with oral CYC and GC were published: 
relapse rates after 12 months (when both medications were stopped) and 24 months did not 
differ between the treatment arms [124].  
In terms of remission maintenance, MMF was inferior to AZA according to the 
IMPROVE trial [125]. In the placebo-controlled WEGT trial, etanercept, when given in addition 
to standard therapy based on CYC and GC for remission induction and maintenance to GPA 
patients, increased the occurrence of solid malignancies [126]. 
T/S, when used as an adjunctive therapy alongside of remission treatment, 
significantly reduced ENT relapses in GPA patients [127]. 
To date, the optimal duration of maintenance treatment remains an open question; 
suggestions vary been 12 and 24 months after remission, although the length of five years has 
been suggested for GPA patients and those who remain PR3-ANCA-positive [108, 128, 129]. 
On the other hand, for MPO-ANCA-positive patients, who are less likely to relapse than PR3-
ANCA-positive patients, maintenance treatment with only low-dose GC for 12 months is 
proposed [130]. 
In a meta-analysis, longer courses of low-dose glucocorticoids for longer than 12 
months were associated with fewer relapses [131]. Relapse-free survival was not better in PR3-
ANCA-positive patients given extended AZA for up to 4 years in comparison to those who 
received AZA for one year [132]. Furthermore, the data from six EUVAS studies with 380 
patients comparing the length of AZA remission treatment indicate that 5-year relapse-free 







2.7.3. Treatment of relapses and refractory disease  
 
Severe relapses should be treated according to the same protocol as used in the induction 
treatment, whereas minor relapses should be treated with the intensification or modification of 
the immunosuppressive medication provided during the maintenance regimen [108]. For 
patients with refractory disease activity, switching the induction medication from CYC to RTX 
or vice versa is recommended [108].  
Deoxyspergualin in combination with GC has shown effects in GPA patients with 
refractory or relapsing disease; however, adverse events were also common [134]. Leflunomide 
or iv immunoglobulins can be used as an alternative for refractory disease [123, 135]. 
 
2.8. ANCA and disease activity 
 
The diagnostic value of ANCA testing, as discussed above, is unquestioned, whereas the clinical 
utility of serial ANCA testing has been debated since its recognition. A meta-analysis of 15 
studies and 828 AAV patients concluded that serial ANCA testing during remission has limited 
value in predicting AAV relapses [136]. In that analysis, pooled positive likelihood ratio (LR) of 
a rise in ANCA predicting a subsequent relapse was 2.84, and positive LR was even lower 
(1.97) if ANCA was persistently positive. In addition, the absence of an ANCA increase could 
not exclude the possibility of relapse because the negative LR of an ANCA increase in 
predicting a later relapse was 0.49. In the subgroup analysis, an increase in P/MPO-ANCA (i.e. 
P-ANCA or MPO-ANCA) was better able to predict future relapse, with positive LR of 10.0 vs 
1.4 for C/PR3-ANCA (i.e. C-ANCA or PR3-ANCA) (p=0.01). However, substantial between-
study heterogeneity was found, including various types of ANCA tests, frequencies of ANCA 
measurement and definitions of ANCA increase, making it difficult to draw clear conclusions 
[136]. Relapse-free survival was significantly longer for patients who remained PR3-ANCA-
negative as compared to PR3-ANCA-positive patients [hazard ratio (HR) of 0.60] [137]. PR3-
ANCA reappearance may also correlate more closely with relapse than persistently positive PR3 
-ANCA [137, 138]. 
Different disease phenotypes seem to behave differently with regards to disease 
activity and its relationship with ANCA levels. GPA patients with active, limited disease are 
more often ANCA-negative than patients with severe disease [44, 139]. In a large AAV cohort 
(N=166) from the Netherlands, in patients with renal involvement, ANCA increases (measured 
with ELISA ANCA methods) were better correlated with relapses than in patients who 
presented with non-renal AAV (HR) of 11.09 vs 2.79, respectively) [140]. This finding was 
confirmed in a PR3-ANCA-positive cohort (N=131) from the RAVE trial, in which ANCA titre 
increased when analysed with direct ELISA (but not with capture ELISA), suggesting an 
increased risk of severe relapse, particularly in patients with renal involvement (HR 7.94) and 
alveolar haemorrhage (HR 24.19) [141].  
The ANCA response to different treatments may also be different. In the RAVE trial, 
PR3-ANCA-negativity was more likely after RTX than after CYC treatment (47% vs 24%, 
respectively) despite the similar clinical efficacy of these treatment arms [109]. Furthermore, a 
follow-up of the same study cohort revealed that increased PR3-ANCA titre was associated with 
an increased risk of relapse in RTX-treated but not in CYC/AZA-treated patients [141].    
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Quite recently, the results from the MAINRITSAN2 trial were published [142]. In that 
trial, the efficacy of two rituximab regimens in terms of maintaining remission did not differ 
significantly: rituximab redoses were administrated either pre-emptively, as determined by 
ANCA status or the reappearance of CD19 lymphocytes, or systematically every 6 months.  
 
 2.9. Outcomes of AAV 
 
2.9.1. Patient outcomes 
 
If left untreated, patient life expectancy after a diagnosis of AAV is dismal; historical data from 
the era before GC and CYC treatment reported a one-year mortality of 80% for GPA [143]. 
Combined treatment with GC and CYC improved the prognosis of GPA patients dramatically 
[104]. The mortality of AAV patients has been declining continuously during the last decades 
[144-146]. The reported 1- and 5-year survival rates based on the surveys of both GPA and 
MPA patients have been 77–91% and 66–78%, respectively, although even better 5-year 
survival rates of up to 89–93% were found in patients diagnosed after 2000 [21, 145, 147]. In 
renal patients, however, 5-year patient survival is 72–84%, even in cohorts diagnosed after 2000 
[118, 146]. In the recent literature, long-term survival at 10 years has varied between 49 and 
81% [145, 148-150], and survival is better in patients without renal involvement than in those 
with renal disease (HR 0.55) [148]. The improved prognosis is mainly attributed to shorter 
diagnostic delay and therapeutic improvements, especially regarding the lower cumulative dose 
of CYC [144]. 
Recently, a meta-analysis of mortality in AAV patients indicated a 2.7-fold increase in 
mortality as compared with the general population [151]. No difference in mortality risk 
between the sexes was found. Studies with only GPA patients indicated a similar risk as studies 
with mixed diagnoses of GPA, MPA and EGPA. In addition, a trend toward improved survival 
over time was found [151]. In a study from Norway conducted on patients with AAGN 
(diagnosed 1981–2012), the standardised mortality ratio (SMR) was 2.8; however, in those 
patients who survived the first year and did not develop ESRD, the age- and gender-adjusted 
SMR was equivalent to that of the general population [152]. 
The most frequently reported negative factor regarding patient survival is advanced 
age [21, 145, 147]. In addition, higher mortality has frequently been associated with decreased 
kidney function at baseline [21, 145, 147]. In contrast, ENT involvement has been associated 
with better patient survival [153]. In a cluster analysis of 673 patients with GPA or MPA, 
patients with renal disease without PR3-ANCA (HR 5.87), patients with cardiovascular AAV 
(HR 6.41) and those with AAV with gastrointestinal involvement (HR 6.74) had a higher risk of 
death than non-renal AAV patients [154]. In patients on chronic dialysis, the 5-year survival rate 
for AAV was only 53%; however, this was comparable to that of non-AAV controls [155].     
In the long-term EUVAS study, the main causes of death within one year after 
diagnosis were active vasculitis (19%) and treatment-associated infections (48%), whereas 
deaths occurring later were mainly attributed to cardiovascular disease (26%), malignancy 




2.9.2. Renal outcomes 
 
In recent studies on AAV patients with renal involvement, the 5- and 10-year renal survival 
rates, i.e., survival without ESRD, were 66–77% and 60%, respectively [149, 156, 157]. 
According to the histopathological classification schema for renal AAV, its subclasses are as 
follows: focal, crescentic, mixed and sclerotic AAGN. In the original article, the predictive 
value of this classification was validated in 100 patients, showing an increased risk of ESRD in 
those with a sclerotic histology [1]. Later, several studies validated the AAGN histology 
classification [149, 156-165]. The results of these studies are shown in Table 3. Overall, renal 
survival was best in patients with focal AAGN, whereas ESRD occurred most often in those 
with sclerotic AAGN. Mixed and crescentic AAGN typically had intermediate outcomes. As 
anticipated, baseline renal function was the most frequently reported independent prognostic 
factor for ESRD [1, 149, 158, 160, 162-164]. Histology class was also found to have an 
independent prognostic effect on renal survival in several studies [158, 160-162]. In three 
validation studies, patients with MPO-ANCA were shown to have an increased likelihood of 




AAV typically presents with fluctuating disease activity, and relapses are common. The 
different definitions of relapse, disease stage, the therapies given, and study settings affect the 
relapse rate. The recommended definition of relapse is the re-occurrence or new onset of disease 
activity attributable to active inflammation caused by AAV [102]. Relapse rates of 34–49% 
within 5 years of follow-up have been reported for AAV patients [98, 146, 166-169]. Recently, 
in the long-term follow-up data for the 10 years after the WEGENT trial, only 30% of patients 
remained relapse-free [150].   
Several studies have reported that patients with C/PR3-ANCA positivity at baseline 
are more prone to relapse [4, 98, 145, 150, 166-169]. Furthermore, C/PR3-ANCA-positivity at 
the time of the switch from induction to remission maintenance therapy is associated with a 
higher relapse rate [170]. In a recent study, however, positive C-ANCA status at stable 
remission was not associated with an increased relapse risk [132]. According to some studies, a 
diagnosis of GPA along with PR3-ANCA-positivity was also a predictor of relapse [98, 166, 
169]. 
Recently, genetic associations with relapse risk have been proposed; the carriage of 
HLA-DPB1*04:01 (more often found in PR3-AAV than in MPO-AAV) was associated with an 
increased risk of relapse [171]. Organ involvement at baseline seems to affect disease activity 
later. Upper respiratory, lung and cardiac involvement are associated with a higher relapse risk 
[167-169]. Kidney function at diagnosis was found to be predictive of the subsequent risk of 
relapse: advanced renal insufficiency was associated with a lower relapse risk, while a better 
GFR was associated with a higher level of risk [150, 168, 169]. 
The CNSAC significantly increased the occurrence of relapse in GPA patients [4, 51]. 
The impact of AAGN histology on relapse risk has not been widely studied. In one study, no 
difference in relapse rate was found [157], whereas in another study, sclerotic AAGN and the 
absence of interstitial infiltrates were associated with an increased risk of renal relapse [172].        
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2.10. Complications of AAV 
 
2.10.1. Thrombotic complications 
 
During the last decade, accumulating data demonstrating a significant increase in VTEs in cases 
of AAV have been presented. The high number of VTEs in adult GPA patients was first 
recognised in a sub-analysis of the WGET trial; during the two-year trial, 8.9% of patients were 
diagnosed with VTE, yielding an incidence of 7.0 per 100 person-years [6]. Soon afterward, 
high incidence rates of VTEs in AAV patients were shown in retrospective cohort studies [173-
175]. In the largest retrospective cohort of 845 patients with AAV, VTE occurred in 7.6% of 
MPA patients and 8.0% of GPA patients during a mean follow-up of 58 months [175]. A long-
term follow-up study from EUVAS found a VTE occurrence rate of 9.8% during a mean follow-
up of 72 months in patients with AAV [176]. The risk of VTE is clearly higher during the active 
phase of the disease [6, 174, 175, 177]. During the first two years after diagnosis, the incidence 
rate ratio was 25.7 for pulmonary embolism (PE) and 20.2 for deep venous thrombosis (DVT) in 
GPA patients as compared to matched population controls [177]. However, after two years, the 
risk for PE disappeared while the risk for DVT remained elevated by 4.5-fold during a median 
follow-up of 7.2 years [177].  
Older age at diagnosis has shown to be a risk factor for VTE in AAV patients [6, 175, 
176]. Higher baseline creatinine (per 100 µmol/l increase, OR 1.17), higher baseline CRP (per 
10mg/l increase, OR 1.05) and previous VTE (OR 3.48) were also associated with higher VTE 
risk [175, 176]. In addition, in AAV patients, the following forms of organ involvement were 
related to VTE risk: stroke with motor deficit (OR 5.82), cutaneous (OR 4.83) and 
gastrointestinal (OR 6.27) [175, 176]. VTE was found less commonly in GPA and PR3-ANCA-
positive patients [174], but this was not confirmed in two other studies [175, 176]. 
The pathogenetic background of the increased frequency of VTE in AAV is still 
poorly understood. Recently, NETs, as a potential bridge between autoimmunity and 
coagulation, have shed light on the pathogenetic background of this phenomenon, as discussed 
above. Common risk factors for thrombosis (such as immobilisation, major surgery, 
malignancy, hormone replacement, oral contraceptive use, diabetes mellitus, obesity, smoking, 
nephrotic range proteinuria and deficiencies of protein, protein S or antithrombin) were not 
recognised in AAV patients with VTE [173, 174]. The prevalence of mutations in factor V 
Leiden, prothrombin and methylenetetrahydrofolate reductase was also not higher in patients 
with GPA and VTE as compared to the general population [178]. In GPA patients, the 
prevalence of antiphospholipid antibodies (aPLAb) was somewhat higher than in the general 
population, although there was no association with VTE [179, 180].  
Disturbances in coagulation markers in AAV patients have been recognised. Elevated 
D-dimer and thrombin-antithrombin complexes were observed in active as compared to 
remission patients in an AAV cohort with creatinine clearance over 25ml/min [181]. In the same 
study, elevated levels of von Willebrand factor (VWF) activity were shown regardless of disease 
activity [181]. Recently, another study showed that because both elevated endogenous thrombin 
potential and increased levels of factor VIII (FVIII) were detected during stable remission, AAV 
patients remain in a hypercoagulable state [171]. In the non-AAV population, high levels of 
FVIII constitute an independent and dose-dependent risk factor for VTE [182, 183]. VWF, 
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having prothrombogenic properties through its involvement in platelet adhesion, activation and 
aggregation, serves as a carrier protein for FVIII and has been suggested as a marker of 
generalised endothelial dysfunction.  
Anti-plasminogen antibodies were identified in patients with AAV, suggesting that the 
fibrinolytic system may be dysregulated; these antibodies also correlated with the presence of 
glomerular fibrinoid necrosis, cellular crescents and more severe renal dysfunction [184]. 
Patients with systemic AAV frequently have impaired kidney function, and renal patients are 
especially at risk of VTEs [185]. Patients with chronic kidney disease (CKD) exhibit increased 
pro-coagulants and a loss of anticoagulant factors, that is, increased levels of tissue factor, 
VWF, factor XIIa, factor VIIa, activated protein C, fibrinogen, plasminogen activator inhibitor-1 
and D-dimer and reduced tissue plasminogen activator [186-188].  
The data concerning the effect of medication use during AAV on coagulation and 
fibrinolysis are scarce. At the population level, the risk of VTE is increased among GC users, 
particularly during the first three months after initiating the treatment [189]. In a rather small 
study, no differences in endogenous thrombin potential were found between AAV patients who 
were given or went without immunosuppressive medication [190]. In a long-term follow-up 
study from EUVAS, treatment with CYC was not significantly associated with VTEs [176]. 
PEX is recommended for patients with severe AAV in order to effectively remove ANCAs 
[108]. In theory, PEX may, per se, have beneficial effects on coagulation, such as the removal of 
procoagulant agents and the use of anticoagulation and replacement fluids during the treatment. 
However, VTE risk was not affected by PEX in a EUVAS cohort [176]. To date, there are no 




In the EUVAS cohort of 524 AAV patients, 24% of patients developed infections, mostly 
bacterial infections of the respiratory tract, during the first year after diagnosis [191]. Infection-
related mortality in this cohort after 1 year was 5.6%. Infection is not only the main cause of 
death during the first year after diagnosis in AAV patients; it also remains an important factor 
contributing to excess mortality later as well [147]. Among 113 French GPA patients, major 
infections (such as bronchopneumonia, herpes zoster recurrence) were reported in 31.0%; of 
these, 39.6% occurred during the first year [192]. However, infection-related mortality in this 
cohort, which had a median follow-up of 3 years, was only 1.8%. Patients who developed 
infections had significantly higher cumulative doses of CYC and GC [192]. Notably, infection 
rates were not different in RCTs comparing RTX and CYC in regimens based on GCs [109, 




Patients with AAV experience an excess risk of cancer development. Historically, the 
standardised incidence ratios (SIR) for cancer at all sites in GPA patients have been about 
double those of the background population [193-195]. The risk of bladder cancer was 
highlighted, with a 3.6–33-fold increased risk. An increased risk of non-melanoma skin cancer 
(SIR 4.7–7.3), lymphoma (SIR 4.2–11.0) and leukaemia (SIR 5.7–5.9) were reported [193-195]. 
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The risk of bladder carcinoma has been associated with the cumulative dose of CYC in 
particular. However, the safe cumulative dose of CYC is not  known precisely, and the dose 
thresholds above which bladder cancer risk is increased have varied from 25 to 36 g in GPA 
patients [194, 195]. Another problem is the latency of cancer development after CYC 
administration. 
In 2011, the cancer data of 535 patients from EUVAS trials were published: during a 
2,650 person-year follow-up, the SIR for cancers at all sites was 1.58 [196]. This result was 
mainly driven by an increased risk of non-melanoma skin cancer (SIR 2.78), and the cancer risk 
for other organs, including bladder cancer, was not statistically significantly increased. These 
results were mainly explained by the reduced cumulative dose of CYC administered to the 
patients, while the role of AZA was also brought up, along with sun-exposure, as a possible 
contributor to the increased SIR seen for non-melanoma skin cancers. Notably, the SIR for all-
site cancers was significant for GPA but not for MPA [196].  
Recently, a retrospective study found that the malignancy risk in CYC-treated patients 
was 4.6-fold higher than in RTX-treated patients, in whom the malignancy risk was comparable 
with that of the general population [197]. 
 
2.10.4. Cardiovascular disease  
  
Patients with AAV are at excess risk of cardiovascular (CV) events. The risk of acute 
myocardial infarction in Danish GPA patients was 2.5-fold higher as compared to the 
background population [198]. In the EUVAS cohort of 535 patients, including both GPA and 
MPA patients, the age-standardised annual CV mortality was 3.7-fold higher than in the 
background population [199]. Within five years of diagnosis, 11.7% of patients with GPA and 
16% of those with MPA undergo at least one CV event. The independent determinants of CV 
outcomes were older age, diastolic hypertension and positive PR3-ANCA status, which was 
inversely related to CV risk [199]. Moreover, CV disease is a major cause of death after the first 
year from diagnosis [147]. Both disease-specific and therapeutic factors likely contribute to the 
increased CV risk in the AAV population. CV risk in this population is also increased by 






3 AIMS OF THE STUDY  
The objectives of the study were as follows: 
 
1. To describe the clinical presentation of biopsy-proven renal AAV at diagnosis, explore the 
outcomes for up to 20 years and assess prognostic factors for renal and patient survival and 
relapse (I). 
 
2. To investigate the association between chronic nasal SA carriage and relapse in AAV patients 
(II). 
 
3. To assess the value of monthly measurements of PR3-ANCA, as detected with nine different 
ELISAs, in monitoring disease activity in GPA patients with early systemic disease (III). 
 
4. To characterise the coagulation profile in patients with renal AAV at the time of diagnosis 






4 PATIENTS AND METHODS 
4.1. Patients and study designs  
  
4.1.1. Study I (Long-term outcome study of renal AAV)  
 
Patients  
The cohort consisted of all consecutive patients diagnosed with renal biopsy-proven ANCA-
positive vasculitis between the years 1996 and 2005 at the Division of Nephrology, Helsinki 
University Hospital. During that time, 85 patients with AAV were diagnosed, including 47 
patients with MPA and 38 patients with GPA.  
 
Study design 
The study design is a retrospective, single-centre, observational cohort study of AAV patients 
with renal involvement. This study is a longitudinal study with a follow-up period of 20 years. 
 
4.1.2. Study II (CNSAC in relation to relapse in AAV patients) 
 
Patients 
The patients in Study II were originally recruited from the two RCTs conducted by the EUVAS 
vasculitis study group. The newly diagnosed AAV patients in these studies were from twelve 
European countries, and the studies were carried out between 1995 and 2002.  
The NORAM trial, including 95 patients, was designed to determine whether oral 
MTX could replace oral CYC as an induction treatment in patients with early systemic GPA or 
MPA without overt renal involvement [115]. The inclusion criteria were as follows: a new 
diagnosis of active GPA or MPA with involvement of one or more organ systems together with 
constitutional symptoms. Patients with organ or life-threatening manifestations of AAV and 
those with creatinine > 150 µmol/l or urinary red cell casts or proteinuria > 1 g/day were 
excluded.     
The CYCAZAREM trial, including 155 patients, compared AZA with oral CYC for 
the maintenance of remission after CYC and steroid-based induction therapy in patients with 
generalised AAV [105]. The inclusion criteria were as follows: a new diagnosis of GPA, MPA 
or RLV with either renal involvement and/or other threatened loss of a vital organ. Patients with 
creatinine > 500 µmol/l were excluded.   
Of the original 250 patients in the NORAM and CYCAZAREM trials, 200 were 
eligible for Study II. Patients with fewer than four nasal cultures, those with early withdrawal or 
death before remission and those lost to follow-up were excluded.  
 
Study design 
This is a prospective, multicentre study of 200 patients with early systemic and generalised 





4.1.3. Study III (PR3-ANCA in monitoring disease activity)  
 
Patients 
The patients in Study III were obtained from the NORAM trial (described above) [115]. Of the 
original 100 patients, 95 were actively treated, and 28 were eligible for the study because they 
were PR3-ANCA-positive and had complete sera series.  
 
Study design 
This study is a prospective, multicentre study of 28 PR3-ANCA-positive, early systemic cases 
of AAV. The duration of the study was 18 months.  
 
4.1.4. Study IV (Coagulation profile of renal AAV patients) 
 
Patients 
A cohort of 21 consecutive patients with newly diagnosed active renal AAV at the Division of 
Nephrology at the Helsinki University Hospital from 2008 to 2011 were included. Of these 
patients, 14 were classified as having MPA, including three patients with renal-limited AAV; 
seven patients had GPA, including one with overlapping GPA and anti-glomerular basement 
membrane disease. A diagnosis of AAV was based on renal biopsy in all but one individual, 
from whom a biopsy could not be safely obtained due to acute coronary syndrome but who 
otherwise had clinically evident MPA. Patients on immunosuppressive treatment for longer than 
one week were excluded.  
Two control groups were created from patients undergoing renal biopsy during the 
same time period. Control Group 1 consisted of 20 patients with mild chronic kidney disease 
(eGFR ≥ 60 ml/min/1.73m2) and no chronic findings in their renal histology. Control Group 2 
included 20 patients with moderate or severe chronic kidney disease (eGFR < 60ml/min/1.73m2) 
and/or sclerotic findings in their renal histology. Patients with diabetes mellitus, a history of 
previous thromboembolic disease, nephrotic syndrome or anticoagulant treatment other than 
low-dose aspirin were excluded from the control groups. 
 
Study design  
This is a prospective, single-centre, observational cohort study conducted with AAV patients 
with renal involvement and patients with other kidney diseases (different glomerulonephritides 
and other nephropathies), who served as controls. All patients were evaluated at diagnosis, and 
AAV patients were followed until remission when the laboratory assessment was repeated. 
 




Table 4. Summary of the patients in Studies I–IV.  
 
Study   Patients’ 
Origin 








































4.2. ETHICAL ASPECTS 
 
Because Study I was a retrospective study and all information was gathered from the patients’ 
medical records, approval from the ethics committee was not required. However, research 
permission from the Department of Medicine in Helsinki University Hospital was granted. The 
approvals for Studies II and III were obtained from local ethics committees of each participating 
centre for the original RTCs, that is, NORAM and CYCAZAREM. Study IV was approved by 
the co-ordinating ethical committee of Helsinki University Hospital. Every patient provided 




4.3.1. Data collection 
 
Study I 
The patients were classified as having GPA or MPA according to the EMA algorithm. Patients’ 
medical records, including baseline clinical data, were systematically reviewed from diagnosis 
until December 31, 2017, death or loss to follow-up. At diagnosis, patients’ ANCA status was 
defined by MPO- or PR3-ELISA. AAV disease activity and organ involvement were assessed 
by BVAS at diagnosis and relapse. The following variables were obtained: kidney function (at 
time of diagnosis, at 3, 5, 10, 15 and 20 years), measured with plasma creatinine and eGFR 
using the CKD-EPI formula [202]; the amount of protein excreted in 24-hour of urine 
collection; dialysis treatment and the occurrence of ESRD.     
 
Studies II and III 
The clinical data were collected from the EUVAS database, in which they were recorded during 
the original NORAM and CYCAZAREM trials. The clinical data were obtained at diagnosis, 
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then monthly until 6 months, and then every three months until the end of the study and at 
relapse. For the purposes of Study II, nasal swabs were obtained at the time of diagnosis and 
then monthly and at relapse during the studies. Of the original 95 patients included in the 
NORAM trial, 84 completed the trial [115]. Of the original 155 patients in the CYCAZAREM 
trial, remission was achieved in 144 patients [105]. Of these, 138 completed the trial. After 
exclusion of patients with fewer than four nasal cultures, 200 patients remained eligible to Study 
II.  
For the purposes of Study III, serum samples were collected locally in the centres and 
then collected and stored centrally at the EUVAS Serum Bank at the Statens Seruminstitut, 
Copenhagen, Denmark. During the NORAM trial, the samples were obtained at entry and then 
monthly and at any clinically suspected relapse. Of the 84 patients who completed the NORAM 
trial, 70 patients were PR3-ANCA-positive. Sera from 45 patients were sent to Statens 
Seruminstitut. Of these patients, 17 were either PR3-ANCA negative or had incomplete series of 
sera. Finally, 28 patients with complete series of sera could be included in Study III. After 
ANCA analyses (described in detail later), the PR3-ANCA results were merged into the original 




The patients were classified as having GPA or MPA according to the EMA algorithm (also 
known as Watts’ algorithm).  The baseline clinical data were recorded, including previous 
history of hypertension, coronary artery disease, smoking and the use of statin or acetylsalicylic 
acid. AAV disease activity and organ involvement were assessed by BVAS at diagnosis and in 
remission. 
The recorded renal variables included kidney function measured by plasma creatinine 
level and GFR (as determined by the CKD-EPI formula [202]), the amount of 24-hour urinary 
protein excretion and dialysis treatment. The blood sample results regarding the activation of 
coagulation and fibrinolysis (described in detail below) were obtained at baseline from each 
patient. In AAV patients, blood samples were re-collected in stable remission. Blood samples 
were available from all 21 AAV patients at baseline whereas after death of two patients and 
removal of one patient to another hospital, blood samples at remission were available from 18 
patients.  
Thromboembolic events during induction treatment were recorded. 
 
4.3.2. Measurement of disease activity 
  
Vasculitis disease activity and organ involvement were scored with the Birmingham vasculitis 
disease activity score (BVAS) [96] (I-IV).   
 
4.3.3. Definitions  
 
Remission was defined as absence of disease activity (BVAS 0) in Studies I and IV. In Studies 
II and III, remission was defined as the absence of new or worse BVAS items allowing minor 
persistent activity in one affected organ (Studies II and III). Relapse was defined as new or 
worsening clinical disease activity requiring the augmentation of immunosuppressive 
medication (Studies I–IV). ESRD was defined as need for permanent dialysis (Study I).  
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4.3.4. Treatment schedules  
 
Studies I and IV 
Induction treatment was based on a combination of GC and CYC, which was given either orally 
(Study I) or iv (Studies I and II). The CYC dose began at 2 mg/kg/d orally and 0.75g/m2 iv at 2–
3 weeks intervals. Dose adjustments were performed based on age and renal insufficiency. CYC 
was given until stable remission was achieved. The initial GC dose was 1 mg/kg, aiming at 10 
mg/day at 6 months, followed by the tapering of the dose. Iv pulses of 500–1000 mg of 
methylprednisolone were given for three days in case of rapidly deteriorating renal function. 
Plasma exchange was considered for patients with alveolar haemorrhage or severe renal failure 
(eGFR < 15 ml/min/m2). Maintenance treatment was mainly based on AZA combined with low-
dose GC. AZA was started at 2 mg/kg, with down-adjustment in elderly patients. However, the 
treatment protocol was not strict, and the medication could be considered individually according 
to the clinical situation.  
 
Studies II and III 
Patients in the NORAM trial were randomised to receive GC combined with either weekly oral 
MTX or daily oral CYC.  [115]. MTX was started at 15 mg/week, escalating the dose to 20-25 
mg/week by 12 weeks, which was then maintained until 10 months and then tapered and 
discontinued at 12 months. CYC was started at a daily dose of 2 mg/kg (maximum 150 mg/day). 
At remission the dose was reduced to 1.5 mg/kg/day until month 10 and then discontinued by 
month 12. Both treatment groups received prednisolone 1 mg/kg/day; the dose was tapered to 15 
mg/day by 3 months and 7.5 mg by 6 months and stopped by 12 months. After discontinuation 
of all treatment at 12 months, patients were followed up for a further 6 months.  
In the CYCAZAREM trial, all patients received the oral CYC-based remission-
induction therapy combined with a tapering course of daily oral prednisolone until remission 
(doses as in NORAM) [105]. Patients in remission between 3 and 6 months were randomly 
assigned to either stop CYC and start AZA (2 mg/kg) or continue CYC (1,5 mg/kg) along with 
prednisolone treatment until 12 months. All patients received daily AZA (1.5 mg/kg) and 
prednisolone (7.5 mg/day) between months 12 and 18 after the trial ended. 
T/S, at prophylactic doses (960mg three times a week) against Pneumocystis jirovecii 
pneumonia, was given according to the local policy of the centre.  
 
4.3.5. Renal biopsy 
  
The renal biopsy indications (Studies I and IV) were microscopic haematuria, proteinuria and/or 
declining renal function. The purpose of renal biopsy was to verify the diagnosis of AAV and/or 
assess the activity of renal disease.   
In Study I, kidney biopsy histology was re-evaluated and classified into four classes of 
AAGN. Those with at least 50% normal glomeruli were classified as focal, those with at least 
50% sclerotic glomeruli were classified as sclerotic, those with at least 50% glomeruli with 
cellular crescents were classified as crescentic and those not in line with the above-mentioned 
criteria were classified as mixed [1]. 
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In Study IV, accessory immunohistochemistry from renal biopsies was produced with 
antibodies against thrombomodulin, CD42b, CD61 and CD39.  Renal biopsies were fixed in 
10% neutral-buffered formalin and embedded in paraffin. Paraffin-embedded specimens were 
cut at 3 μm using conventional histological techniques and stained for Haematoxin-Eosin, Jones 
Methenamine Silver, Masson Trichrome and Congo for histological analysis. For 
immunohistochemistry the sections were transferred to electrostatically charged glass slides 
(SuperFrost® Plus, Menzel-Gläser, Braunschweig, Germany). Slides were stained with a fully 
automatic immunohistochemical system Benchmark LT (Ventana Medical Systems, Illkirch, 
France) using standard cell conditioning with a biotin-free multimer-based detection system 
(ultraView™ Universal DAB, Ventana Medical Systems). Antigen expression was examined 
using the following mouse monoclonal primary antibodies against thrombomodulin 
(Novocastra, clone 15C8, diluted 1:100, incubated 48 min at 25°C), CD42b (Novocastra, clone 
MM2/174, diluted 1:100, incubated 32 min at 37°C), CD61 (Novocastra, clone 2f2, diluted 
1:100, incubated 32 min at 37°C), and CD39 (Novocastra, Newcastle Upon Tyne, UK, clone 
22A9, diluted 1:25, incubated 44 min at 37°C). To achieve a darker signal, Amplification Kit 
(Ventana Medical Systems) was used for CD39, tissue factor and thrombomodulin. 
Haematoxylin (Ventana Medical Systems) and Bluing Reagent (Ventana Medical Systems) 
were both used as counterstains (4 minute + 4 minute). 
Scoring of the immunochemistry was done semiquantitatively. Thrombomodulin 
identifies endothelial cells and leukocytes. It was scored as follows: 1 indicates < 10% capillary 
positivity; 2 indicates 10–50% positivity; and 3 indicates > 50% positivity. CD42b identifies 
platelets and megakaryocytes and thrombin receptor. It was scored as follows: 1 indicates single 
platelets in glomeruli or interstitial tissue or peritubular capillaries; 2 indicates several platelets 
scattered around; and 3 indicates platelet aggregates in capillaries and glomeruli. CD61 
identifies platelets, megakaryocytes, monocytes, macrophages and endothelial cells. It was 
scored in a similar way as CD42b, with the addition of class 0 which indicates negative staining. 
CD39 is a transmembrane glycoprotein that also identifies lymphocytes. It was scored as 
positive (class 1) or negative (class 0) in endothelial cells. 
 
4.3.6. S. aureus nasal carriage 
  
In Study II, nasal cultures were taken at diagnosis and then planned to be re-examined monthly 
and at relapse. The swabs were taken by firmly rotating a sterile cotton-tipped swab along the 
anterior nares and then incubating such swabs for 48 h at 35°C. The identification of coagulase-
positive isolates was based on typical appearance upon slide coagulase testing and the ability to 
leave DNA. The patient was defined as a chronic carrier of S. aureus when ≥ 75% of at least 
four nasal cultures were positive for S. aureus. When all cultures we negative for S. aureus, the 
patient was defined as S. aureus-negative. All other patients received intermittent carrier status. 
 
4.3.7. PR3-ANCA detection, identification of peak value and definitions of increments 
  
In Study III, a serum sample to examine PR3-ANCA was taken at entry, then monthly and at the 
time of clinically suspected relapse. Nine PR3-ANCA ELISA assays were applied to measure 
the levels of PR3-ANCA: three direct ELISAs, four capture ELISAs using human native PR3 
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only and two direct ELISAs using human recombinant PR3 (human cDNA expressed in human 
cells, Euroimmun), one of which used a mixture of human native and human recombinant PR3. 
All assays were performed in accordance with the manufacturers’ instructions, and all values 
were recorded as exact values. In cases with values exceeding the upper reading limit, dilutions 
were used to obtain exact values. 
Phadia performed the aliquoting and labelling of all samples for the study. Phadia also 
performed the Varelisa PR3 ANCA and Varelisa PR3 capture ELISAs. All samples were 
examined by Statens Seruminstitut using a third-generation anchor anti-PR3 assay (Anti-PR3 
HS ELISA, ORG 618, ORGENTEC Diagnostika GmbH, Germany). EuroDiagnostica 
performed direct ELISA and capture ELISA. Euroimmun performed four different ELISAs: 
three direct ELISAs coated with human PR3, human recombinant PR3 or a mixture of human 
and human recombinant PR3, as well as one capture ELISA using human PR3. 
Because the PR3-ANCA values from the different assays were based on different 
units and reference sera, the PR3-ANCA values from all nine assays were transformed into 
logarithmic values. The sums of the logarithmic values at each month for each patient were then 
calculated. The highest sum value was then identified as the ‘PR3-ANCA peak value’. This 
peak value could be identified in relapsing and non-relapsing patients, making it possible to 
compare increments related to the peak values in both groups. 
For each assay, the increments in absolute PR3-ANCA values were calculated A) 
from time of remission until the time of the peak value defined above, B) from the previous 
month until the time of the peak value or C) from the previous month for all timepoints after 
month 4. The two increments prior to the peak values (A and B) were compared between the 
relapsing and non-relapsing groups. The largest monthly increment after remission (C) was 
recorded in order to determine whether it coincided with the time of relapse in each of the nine 
assays for each of the relapsing patients. 
 
 4.3.8. Markers of activation of coagulation and fibrinolysis 
  
In Study IV, blood samples were collected from the AAV patients twice, first during the active 
phase of the disease and again when the patient was in remission. Blood samples were obtained 
from the control patients only at baseline, i.e., at the time of the renal biopsy. 
Citrate-anticoagulated (109 mM sodium citrate) samples were centrifuged at 2,500 g 
for 10 min, and the separated plasma samples were frozen at -70°C. Laboratory analysis 
consisted of plasma prothrombin time (Nycotest PT, Axis-Shield PoC As, Oslo, Norway), 
activated partial thromboplastin time (Actin FSL), thrombin time (BC Thrombin Reagent), 
antithrombin activities (a chromogenic assay, Berichrom Antithrombin III), fibrinogen (a 
modification of the Clauss method, Multifibren U), FVIII activity (FVIII:C) (one-stage clotting 
assay, Pathromtin SL and Coagulation Factor VIII Deficient Plasma), vWF antigen (VWF:Ag 
with VWFag Latex Reagent) and ristocetin cofactor activity (VWF:RCo with BC von 
Willebrand Reagent), all of which were analysed with a BCS XP analyser (Siemens Healthcare 
Diagnostics, Marburg, Germany) and prothrombin fragments (F1+2) (enzyme immunoassay 
Enzygnost F1+2, monoclonal). All reagents were obtained from Siemens Healthcare 
Diagnostics (Marburg, Germany). D-dimer was measured with an immunoturbidimetric assay 
(Tina-quant D-Dimer, Roche Diagnostics, Mannheim, Germany).  
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Lupus anticoagulant was detected using two screening tests based on activated partial 
thromboplastin time (IL Test APTT-SP, Instrumentation Laboratory, Italy) and Russell Viper 
Venom activated clotting time (DVVtest 10, American Diagnostica Inc). Anti-cardiolipin and 
anti-beta2 glycoprotein I (specific phospholipid antibodies of the IgG class) were detected with 
immunological assays (Varelisa cardiolipin IgG antibodies and beta-2-glycoprotein I IgG 
antibodies, Phadia GmbH, Freiburg, Germany, respectively) with reference values of < 15 U/ml. 
To assess the accumulation or load of acquired coagulation abnormalities, a score was 
calculated, including the abnormality of the following variables: thrombocytosis, short TT, low 
AT, high fibrinogen, FVIII:C, VWF:Ag, VWF:RCo, F1+2 and D-dimer (one point for every 
variable), providing a total score of 0–9. 
 
4.3.9.  Other assays 
 
In Studies I and IV, plasma creatinine was measured by a photometric, enzymatic method. 
Plasma CRP was measured by a photometric immunochemical method. Blood haemoglobin was 
measured photometrically and blood cells with an impedance measurement. Urine protein was 
measured from a 24-hour collection with photometric method using benzetonium chloride. 
MPO- and PR3-ANCA were measured with direct ELISA methods. 
In Study III, analyses other than ANCA, and in Study II, all analyses were done 
locally. 
 
4.3.10. Statistical methods   
 
Analyses were performed using IMB SPSS Statistics for Windows (versions 22.0-25.0) (Studies 
I, II and IV) and S-PLUS program (Study III). P-values < 0.05 were considered statistically 
significant. 
The variable distributions were checked using Kolmogorov-Smirnov test and/or 
graphical plots. For normally distributed baseline characteristics and primary response variables, 
means and standard deviations (SD) were provided. For non-normally distributed data, variables 
were described as medians with ranges or medians with interquartile ranges (IQR, 25th–75th 
percentiles).  The logarithmic transformation was used for variables skewed to the right, when 
appropriate, to normalise the distributions (IV). 
Relations between two categorical variables were analysed by Chi-squared test or 
Fisher’s exact test (I, II). Correlations between continuous variables were calculated using 
Pearson’s correlation (r) for normally distributed (IV) and Spearman’s rank (rho) coefficients 
for non-normally distributed variables (I, IV).  
Associations with categorical and continuous normally distributed variables were 
analysed with analysis of variance (ANOVA) or t-test for independent samples depending on the 
number of categories: more than two categories or two categories, respectively (II, IV). 
Association between categorical variables and continuous non-normally distributed variables 
was analysed with Kruskal-Wallis test or Mann-Whitney U-test, also depending on the number 
of categories (more than two categories or two categories, respectively) (III, IV). After analysis 
of variance and Kruskal-Wallis test, Bonferroni corrections were used when appropriate (I, IV). 
Non-parametric Friedman's two-way ANOVA was used to analyse more than two repeated 
43 
 
measurements (I). Paired samples t-test and non-parametric Wilcoxon signed-ranks test were 
used to evaluate change between two repeated measurements (III, IV). 
Univariate logistic regression was performed to study associations between prognostic 
factors and binary endpoints (II). The results were given as odds ratios (ORs) with 95% 
confidence intervals. Kaplan-Meier method was used to draw event-free survival curves and to 
estimate event-free survival rates (I, II). Univariate Cox-proportional hazards models were used 
to assess the associations between potential prognostic factors and the time without event (I, II). 
Multivariate analyses were performed to find the most important predictors, and predictors of 
significance P < 0.10 in univariate model were introduced into the models by forward stepping 





5.1.  Clinical and histological presentation of renal AAV patients and 
outcomes of 20-year follow-up (Study I)  
 
5.1.1. Patient characteristics at baseline 
  
Of 85 patients, 53 (62.4%) were men, and 47 (55.3%) had MPA. Of MPA patients, 87.2% were 
MPO-ANCA-positive, whereas 89.5% of GPA patients were PR3-ANCA-positive. GPA 
patients were younger than MPA patients [medians of 52 years (range 22–77) vs 62 years (28–
80), respectively, p=0.004], and their GFR at diagnosis was better preserved than in MPA 
patients [medians of 35 ml/min/1.73m2 (3–120) vs 17 ml/min/1.73m2 (1–91), respectively, 
p=0.01]. In most patients (76.5%), the amount of proteinuria was non-nephrotic (i.e. ≤ 3g/day), 
with no difference between diagnostic subgroups. The diagnostic delay was four months (IQR 
2–6), without any difference between MPA and GPA patients. 
 
5.1.2. Histopathological classes of AAGN  
 
Kidney biopsy was available from 84 patients. The histopathological class of AAGN was focal 
in 34.5%, crescentic in 26.2%, mixed in 20.2% and sclerotic in 19.1% of patients. The 
demographic and clinical data of patients in various histopathological classes are given in Table 
5. 
 
































Males 17 (58.6) 15 (68.2) 9 (52.9) 11 (68.8) 52 (61.9) 0.71 






















Proteinuria >3 g/day 2 (6.9) 4 (18.2) 5 (29.4) 8 (50.0) 19 (22.6) 0.01 
Data are presented as the median (range) for continuous non-normally distributed variables and as the number (%) for categorical 
variables. 
 
5.1.3.  Induction and maintenance treatment 
 
Follow-up data were available on 82 patients and the median follow-up time was 16.2 years 
(95% CI 14.9–17.7). Regarding induction medication, 81.7% (67/82) of patients were given a 
combination of CYC and GC. CYC was given iv to 61.2% and orally to 38.8% of the patients. 
The cumulative dose of oral CYC was higher than that of iv CYC [median 13.3 g (IQR 7.4–
21.0) vs 9.5 g (7.0-12.0), p=0.01]. Almost all GPA patients (97.3%) and 68.9% of MPA patients 
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were treated with CYC (p=0.001). CYC treatment was given to all patients with crescentic 
AAGN, 85.2% of patients with focal AAGN, 82.4% of patients with mixed AAGN and 53.3% 
of patients with sclerotic AAGN (crescentic vs sclerotic, p=0.002). PEX was given to 8.5% of 
the patients and 3.7% were treated with iv immunoglobulin. Altogether 96.3% of patients 
received maintenance treatment. A combination of AZA and GC was the most common 
medication and was given to 79.2% of the patients. The other maintenance treatments used were 
GC alone (10.4%) or in combination with CYC (3.9%) or MMF (5.2%). 
 
5.1.4. Patient survival and causes of death 
 
Forty deaths occurred during the follow-up, yielding a patient survival rate of 45% at 20 years 
(95% CI 31.2–59.2). The median survival time was 18.2 years (95% CI 13.2–23.2). The 1-, 5-, 
10-, and 15-year patient survival rates were 96% (95% CI 92.3–100), 88% (95% CI 80.7–94.9), 
71% (95% CI 60.9–80.6) and 55% (95% CI 44.3–66.2), respectively (Figure 4). 
 
Figure 4. Patient survival.  
(Salmela A, Törnroth T, Poussa T, Ekstrand A. Int J Nephrol 2018; 2018:6360814. Reprinted with permission from 
the copyright holder.) 
 
Two patients died within 3 months, without achieving remission; one death was 
related to active disease (intracerebral haemorrhage), and another was related to treatment 
(opportunistic infection with cytomegalovirus and Pneumocystis jirovecii-pneumonia). A third 
death within the first year after diagnosis occurred at 7 months and was due to neutropenic 
sepsis following immunosuppressive medication. The cause of death was available for 82.5% of 
patients. The major causes of death were infections (27.3%), cardiovascular diseases (24.2%) 
and malignancies (21.2%). In 9.1% of patients, death was directly related to vasculitic disease 
activity. In a multivariate analysis, age ≥ 58 years (HR 7.64; 95% CI 3.44–16.95; p<0.001) and 






5.1.5. Kidney function and renal survival 
 
Among patients who required dialysis within one month after diagnosis, 38.5% experienced 
reversible renal failure. During the follow-up period, a total of 25 patients developed ESRD, 
yielding an overall renal survival rate of 68% (95% CI 57.1–78.2). One-year renal survival was 
84% (95% CI 76.2–92.0), 5-year renal survival was 79% (95% CI 70.1–87.9), and 10-year renal 
survival was 71% (95% CI 60.5–80.8). Two cases of ESRD occurred after 10 years, the last of 
which occurred at 11.3 years, as shown in Figure 5. 
 
 
Figure 5. Renal survival.  
(Salmela A, Törnroth T, Poussa T, Ekstrand A. Int J Nephrol 2018; 2018:6360814. Reprinted with permission from 
the copyright holder.) 
 
In a multivariate analysis, male gender, GFR < 30 ml/min/1.73m2 and presence of MPO-ANCA 
were related to worsened renal survival (HR 0.026; 95% CI 0.10–0.73, p=0.01 for female 
gender, HR 4.10; 95% CI 1.35–12.49, p=0.01 for GFR < 30 ml/min/1.73 m2, and HR 3.10; 95% 
CI 1.21-7.95, p=0.02 for MPO-ANCA, respectively). Across histopathological classes, renal 
survival was as follows: 88% in focal, 71% in crescentic, 56% in mixed and 37% in sclerotic 
AAGN (p=0.01, Figure 6).  
 
 
Figure 6. Renal survival according to histopathological classes. 
(Salmela A, Törnroth T, Poussa T, Ekstrand A. Int J Nephrol 2018; 2018:6360814. Reprinted with permission from 





Relapse-free survival was 47% (95% CI 36.1–58.4) at 5 years, 30% (95% CI 19.1–40.8) at 10 
years, 26% (95% CI 15.0–36.6%) at 15 years and only 10% (95% CI 0.0–24.7) at 20 years. The 
median time to the first relapse was 4.6 years (95% CI 3.0–6.2). In a multivariate analysis, 
diagnosis was the only significant predictor of relapse-free survival; in patients with GPA, the 
time to relapse was shorter than in patients with MPA (3.4 years, 95% CI 1.3–5.5 vs 5.9 years, 
95% CI 0.9–10.9; HR 0.48, 95% CI 0.28–0.82; p=0.01). 
During the 20-year follow-up period, 68.3% of patients had at least one relapse, 
39.0% had more than one relapse and the total number of relapses was 129. Of these relapses, 
40.3% were renal relapses. Across histopathological classes, the time to first relapse was 3.4 
years (95% CI 1.9–5.0) in crescentic, 4.8 years (3.3–6.2) in focal, 5.5 years (0.0–15.7) in mixed 
and 7.4 years (3.6–11.3) in sclerotic AAGN (p=non-significant). The median number of relapses 
according to AAGN class was two (range 0–7) in focal, 1.5 (0–7) in crescentic, one (0–4) in 
mixed and 0 (0–3) in sclerotic AAGN (p=0.02).   
At the time of the first relapse, 55.4% of the patients were without 
immunosuppression, 35.7% used AZA, and 8.9% received only GC. No difference in relapse 
rates was observed with respect to CYC administration route (iv vs oral, p=0.11).  
AZA combined with GC was used as a relapse treatment in 41.1%, CYC in 23.3%, 
GC alone in 13.9%, MMF in 12.4% and MTX or cyclosporine in 2.3% of the relapses. From the 
year 2011 onward, the relapses of five patients (nine relapses altogether) were treated with RTX.   
  
5.1.7. Severe infections during the first year 
 
Infections requiring hospitalisation during the first year after diagnosis occurred in 32.0% of 
patients. Three patients had more than one event, and altogether 34 events were recorded. The 
most common infections were pneumonia (N=11) and septicaemia (N=10). Leucopenia (defined 
as leucocytes <3.5 x109/l) was associated with eight events. In a multivariate analysis, female 
gender (HR 0.32; 95% CI 0.12–0.84, p=0.02) and GFR < 60 ml/min (HR 9.04; 95% CI 1.22–
66.78, P=0.03) were significant predictors of infection. 
 
5.2. CNSAC in relation to relapse in AAV patients (Study II)  
 
5.2.1. Patient characteristics 
 
Of 200 patients, 48.5% were men, and 75.5% had GPA, 18.0% had MPA and 6.5% were 
diagnosed with a renal-limited form of AAV. In 58.5% of the patients, AAV was generalised 
(patients from the CYCAZAREM trial), and 41.5% had early systemic AAV (patients from the 
NORAM trial). ANCA specificities were distributed as follows: 71.5% of the patients were 
PR3-ANCA-positive, 25.0% were MPO-ANCA-positive and 3.5% were ANCA-negative. 
Patients with early systemic AAV were younger and exhibited nasal disease activity at entry 
more often than patients with generalised AAV [median 50.5 (range 18–78) vs 55.9 (20–76) 




5.2.2. S. aureus nasal carriage status 
 
The total number of nasal swabs was a median 12 (range 4–19) per patient. In the entire cohort, 
12.0% were chronic nasal S. aureus carriers, 51.0% were intermittent carriers and 37.0% were 
negative for S. aureus. The distribution of nasal S. aureus carrier status was not significantly 
different in patients with early systemic as compared to generalised AAV (p=0.57). However, 
CNSAC was almost solely seen in GPA patients so that 23 out of 24 with CNSAC were GPA 
patients. Thus, the risk of CNSAC was higher in GPA patients (OR 8.63, 95% CI 1.13–65.6, 
p=0.04). Furthermore, CNSAC was more common in patients with nasal SA positivity at entry 
(OR 6.90, 95% CI 2.51–18.97; p<0.001). 
Prophylactic T/S treatment was used in 27.5% of patients and was associated with a 
reduced risk of CNSAC (3.6% among T/S-treated vs 15.2% among non-T/S-treated patients, 
OR 0.21, 95% CI 0.05–0.93; p=0.04). Of the GPA patients who were not treated with T/S, 
19.3% were chronic nasal carriers of S. aureus. 
 
5.2.3. Relapse rate and associations with nasal S. aureus carriage 
 
Relapse occurred in 32.5% of patients. The relapse rate was higher in early systemic patients 
than in those with generalised AAV (55.4% vs 16.2%; OR 6.41, 95% CI 3.33–12.34, p< 0.001). 
Relapse occurred in 41.7% of patients with CNSAC (all GPA), in 31.4% patients who were 
intermittent SA carriers and in 31.1% of non-carriers (p=0.59). Thus, for all AAV patients, no 
association between CNSAC and relapse was observed (OR 1.57, 95% CI 0.66–3.76; p=0.31). 
However, the relationship between CNSAC and relapse differed based on disease 
severity: in patients with generalised AAV and CNSAC, a higher risk of relapse was observed 
(OR 4.64, 95% CI 1.29–16.67; p=0.02) in contrast to patients with early systemic (i.e. milder) 
AAV and CNSAC (OR 0.52, 95% CI 0.15–1.81; p=0.31). The same was true in GPA patients: 
in those with generalised disease, an association between CNSAC and relapse was observed 
(HR 4.10, 95% CI 1.37–12.25; p=0.01) (Figure 7). In GPA patients with early systemic disease, 
no association was found (HR 0.76, 95% CI 0.30–1.92; p=0.56) (Figure 8). In the NORAM trial 
(that is, in patients with early systemic disease), immunosuppression was terminated early, at 12 
months, resulting in a high number of relapses afterwards. When the time to the first relapse was 
analysed for the first 12 months only, CNSAC in GPA patients was associated with a trend to an 
increased relapse risk (HR 2.73, 95% CI 0.95–7.87; p=0.06). 
 
5.2.4. Relapses related to prophylactic T/S treatment 
 
Prophylactic T/S treatment was not associated with reduced relapse rate because in the patients 
who were treated with the prophylactic T/S, relapse occurred in 27.3% of cases, as compared to 







Figure 7. Time to first relapse in GPA patients with generalised disease. 
(Salmela A, Rasmussen N, Cohen Tervaert J-W, Jayne D, Ekstrand A. Rheumatology 2017; 56(6):965-72. 
Reprinted with permission from the copyright holder.) 
 
 
Figure 8. Time to first relapse in GPA patients with early systemic disease. 
(Salmela A, Rasmussen N, Cohen Tervaert J-W, Jayne D, Ekstrand A. Rheumatology 2017; 56(6):965-72. 
Reprinted with permission from the copyright holder.) 
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5.3. PR3-ANCA in monitoring disease activity (Study III) 
 
5.3.1.  Patient characteristics 
  
In this cohort, all 28 patients had GPA and were PR3-ANCA-positive. Of these patients, 42.9% 
were males. MTX was given to 53.6%, and 46.4% of patients were treated with CYC. Of these, 
16 experienced relapse (relapsing patients), whereas twelve maintained remission (non-relapsing 
patients). Of the relapses, 68% included ENT activation, and renal activation was observed in 
32% of these relapses. 
 
5.3.2. PR3-ANCA profiles during the study 
 
In general, in all assays, both in relapsing and non-relapsing patients, PR3-ANCA values 
decreased from entry to remission (by month four), when the lowest values were recorded, and 
then increased again when medication was reduced. We observed that in relapsing patients, 
PR3-ANCA declined again after relapse when medication was re-induced or augmented, while 
in non-relapsing patients, PR3-ANCA values continued to rise or remained unchanged. No 
significant differences were observed in PR3-ANCA profiles between treatment arms. 
 
5.3.3. PR3-ANCA values in relation to relapse status 
 
To compare changes in PR3-ANCA after remission between the relapsing and non-relapsing 
patients, the PR3-ANCA peak value was calculated from all assays performed for each patient. 
In relapsing patients, the peak value was reached at a median of 14 months (range 6–17 
months), which corresponded with relapse in 14 patients and was within 1 month of relapse in 
two patients based on imputed values. In non-relapsing patients, the peak value occurred at a 
median of 12 months (median, range 6–17). 
In general, the median PR3-ANCA value at relapse in relapsing patients was higher 
compared to the median peak value in non-relapsing patients. However, this difference was 
significant only in two capture assays (Phadia’s, p=0.002 and EuroDiagnostica’s, p=0.033, 
respectively). Nevertheless, due to a large overlap between the values at relapse and the peak 
values in non-relapsing patients, the assays performed could not identify a relapse.  
Regarding the increments in PR3-ANCA values from remission to relapse or peak value (in 
non-relapsing patients), these increments were significantly higher in relapsing as compared to 
non-relapsing patients upon Euroimmun’s direct ELISA using human recombinant PR3 and 
Phadia’s capture ELISA assays (p=0.002 and p=0.034, respectively). The increments in PR3-
ANCA since the month previous to relapse in relapsing patients as compared to such increments 
since the previous month until the peak value was reached in non-relapsing patients did not 
differ in any assay. The largest monthly PR3-ANCA increment after remission was not 
significantly related to relapse. Entry values were significantly higher in relapsing patients as 
compared to non-relapsing patients in three assays (Euroimmun’s direct ELISA, p=0.019; 




5.4. Coagulation profile in renal AAV patients as compared with other 
renal patients (Study IV) 
 
5.4.1. Characteristics of and outcomes for AAV patients 
 
Of 21 AAV patients, 16 (76.2%) were men, and 14 (66.7%) had MPA. One such patient had 
overlapping GPA and anti-glomerular basement membrane disease. The ANCA specificities in 
the diagnostic groups were distributed as follows: among MPA patients, 92.9% were MPO-
ANCA-positive, and among GPA patients 85.7% were PR3-ANCA-positive. Their median GFR 
at diagnosis was 21 ml/min/1.73m2 (range 7–45), and while in remission (at a median of 6.1 
months, range 3.2–18.3), this was 35 ml/min/1.73m2, p=0.15. Eighteen patients reached 
remission, two patients died before remission and one patient was moved to another hospital 
soon after the diagnosis. Altogether seven patients required dialysis; of these, kidney function 
was reversible in two (28.6%).  
Two thromboembolic events occurred in AAV patients: one MPA patient was 
diagnosed with a DVT (3 months after diagnosis), and one GPA patient was diagnosed with a 
PE (4 months after diagnosis). In addition, one lethal, acute myocardial infarct occurred during 
active AAV (2 months after diagnosis).  
 
5.4.2 Laboratory markers of coagulation and fibrinolysis in AAV patients 
 
To assess the activation of coagulation and fibrinolysis, blood samples were obtained during the 
active phase of the disease and re-collected during remission (Table 6). 
 
Table 6. CRP, haemoglobin, platelet count and coagulation variables in AAV patients during 







CRP 113 (19-134) 2 (2-5) <0.001 <3 mg/l 
Haemoglobin 105 (91-134) 122 (119-141) 0.01 1           134-167 g/l** 
Platelets 290±116 224±59 0.01 150-360 E9/l 
Prothrombin time 123±19 145±19 0.001 70-130% 
Thrombin time 17 (16-17) 17 (16-19) 0.11 17-25 s 
Antithrombin activity 99±15 116±14 <0.001 8           4-108% 
Factor VIII 228 (187-266) 191 (177-256) 0.56 52-148% 
VWF:Rco 198 (164-292) 196 (170-304) 0.86 44-183% 
VWF:Ag 222 (168-266) 193 (165-236) 0.21 50-169% 
Fibrinogen 6.9±2.6 5.2±1.5 0.007 1.7-4.0 g/l 
F1+2 563 (385-730) 212 (184-318) 0.001 69-229 pM/l 
D-dimer 3.0 (1.1-6.6)  0.6 (0.2-0.8) 0.001 ≤ 0.5 mg/l 
CRP = C-reactive protein; VWF:Rco = von Willebrand factor ristocetin cofactor activity; vWF:Ag = von Willebrand factor 
antigen; F1+2 = prothrombin fragments. Data are presented as means ± standard deviations or medians (25th–75th 
percentiles).  
* Two AAV patients died before blood samples were obtained in remission and one patient was moved to another 




F1+2 was markedly elevated at diagnosis. It was high (above the median) in all 
dialysis patients (one of whom died) and in two out of three patients who needed dialysis within 
one month after diagnosis, as well as in the two patients who developed thromboembolic 
complications later (Figure 9). The four patients with the lowest F1+2-values (< 25% quartile) 
had low disease activity without complications. 
D-dimer levels were substantially elevated during the acute phase of the disease. Only 
four patients, all with lower disease burdens and uncomplicated disease courses, had normal D-
dimer levels at diagnosis (Figure 8). Furthermore, D-dimer levels were positively correlated 
with disease activity (BVAS) (r=0.52, P=0.02). Both D-dimer and F 1+2 values decreased 
toward remission; however, the median D-dimer level remained above the normal range during 
remission. In active AAV, F1+2 and D-dimer levels were negatively correlated to GFR, 
although there was no such correlation during remission.  
Fibrinogen levels decreased from the active phase of disease to remission although 
they did remain elevated during remission as well. High levels of FVIII, VWF:RCo and 
VWF:Ag were found in both the active and remission phases of AAV. No aPLAbs were 
observed. 
 
Figure 9. F 1 + 2 and D-dimer levels in AAV patients during active AAV and remission. 
(Salmela A, Ekstrand A, Joutsi-Korhonen L, Räisänen-Sokolowski A, Lassila R. Nephrol Dial Transplant 2015; 





5.4.3. Patient characteristics in the control groups 
 
The patients in Control Group 1 were younger than the AAV patients [median 44 years (range 
21–66) vs 60 (18–84), p=0.03]. The kidney function was clearly better in these control patients 
than in the AAV patients at diagnosis [91 ml/min/1.73m2 (IQR 66–107) vs 21 (7–45), p<0.001]. 
In Control Group 2, the median age was 57.5 years (range 25–77), and median GFR was 44 
ml/min/1.73m2 (IQR 31–50), with no significant differences as compared to AAV patients.  The 
most common diagnosis in both control groups was IgA GN (N=12 in Control Group 1, and 
N=8 in Control Group 2). In Control Group 2, chronic changes were found in seven patients 
(nephrosclerosis N=4, chronic tubulointerstitial nephritis N=2 and ESRD N=1). 
In the control groups, follow-up data were available for up to one year for 32 (80%) 
patients, and no VTE was detected. 
 
5.4.4. Laboratory markers of coagulation and fibrinolysis in the control groups 
 
In Control Group 1, the median/mean values for all tests related to coagulation activity and 
fibrinolysis were within the normal range, with the exception of fibrinogen, which was elevated 
(mean 4.5g/l, SD ±1.3). 
In Control Group 2, the values of plasma prothrombin time (138%, ±24), FVIII (median 169%, 
IQR 141–194), fibrinogen (5.2g/L, ±2.0) and F1+2 (244pM/l, 188–283) were above the normal 
range. When patients in Control Group 2 were compared to patients with active AAV, 
significant differences were seen in VWF:RCO [median 165% (IQR 95–182) vs 198% (164–
292), p=0.04], VWF:Ag [160% (IQR 107–192) vs 222% (168–266), p=0.04] and fibrinogen 
(mean 5.2 g/l ±2.0 vs 6.9 ±2.6, p=0.02) and even more clearly in F1+2 [median 244 pM/l (IQR 
188–283) vs 563 (385–730), p=0.002] and D-dimer [median 0.3 mg/l (IQR 0.2–0.5) vs 3.0 (1.1–
6.6), p=0.002], whereas in comparison with the remission values, no significant differences 
were found.  
 
5.4.5. Load of coagulation abnormalities for the AAV patients and control groups   
 
The load of acquired coagulation abnormalities decreased in AAV patients from the active phase 
to the remission phase of the disease (p=0.04), as shown in Figure 10. During remission, the 
load of acquired coagulation abnormalities was comparable to that of patients in Control Group 
2.  




Figure 10. The cumulative load of coagulation abnormalities during the active and remission 
phases in AAV patients and in control patients. 
(Salmela A, Ekstrand A, Joutsi-Korhonen L, Räisänen-Sokolowski A, Lassila R. Nephrol Dial Transplant 2015; 
30(Suppl 1):53-9. Reprinted with permission from the copyright holder.) 
 
5.4.6. Immunohistochemistry from renal biopsies 
 
The results of immunochemistry from renal biopsies are given in Table 7. No significant 
differences between AAV and control patients were found in the staining patterns of 
thrombomodulin, CD42b, CD61 or CD39. Typical staining patterns are shown in Figure 11. 
 
Table 7. Immunohistochemistry in AAV and control patients  
 
Staining and scoring  AAV patients 
N=20 (%) 
Control patients 
N=40 (%) * 
P 
Thrombomodulin  1 
                              2 








CD42b                  1 
                              2 








CD61                    0 
                              1 
                              2 










CD39                    0 






AAV = ANCA-associated vasculitis. *in Thrombomodulin N=39; in CD61 N=37 due to the shortage of biopsy material. Scoring of 





Figure 11. Typical staining patterns in immunohistochemistry. Endothelium of peritubular 
capillaries and injured glomeruli tuffs are stained positively with thrombomodulin (A). In 
CD42b staining, clusters of platelets are shown in the injured areas (crescents) (B). CD39 was 
expressed in the endothelium of all arterial walls and in some capillaries (C). CD61 was 




6 DISCUSSION  
This study concerns the outcomes of AAV. Factors related to prognosis and disease activity are 
dealt with in a series of studies. In addition, special attention was placed on measuring 
alterations of coagulation status and ANCA levels in relation to disease activity. These issues 
were studied in four populations. Two of these included patients with AAV with renal 
involvement from a single Finnish centre, and two included AAV patients recruited for two 
clinical trials performed by the EUVAS group. 
 
6.1. Patient survival 
 
Due to induction treatment based on GC and CYC, the survival rate for AAV patients has 
improved dramatically over time. Our results suggesting a patient survival of 88% at five years 
(Study I) are in accordance with recent studies reporting a 5-year patient survival rate of about 
90% [21, 145, 147], although this value is usually lower in renal cohorts [119, 146]. Previously, 
a lower 5-year survival of 74% was reported in a Finnish population of GPA patients by Takala 
et al. [203]. In that cohort of 492 GPA patients diagnosed between 1981 and 2000 from all over 
Finland, prognoses were unchanged between the first and the second 10-year period, the latter of 
which (1991–2000) overlaps with our study period. In recent renal AAV cohorts, the 10-year 
patient survival rate has varied between 49 and 81% [145, 149], and we found a survival of 
71%. At 20 years, 45% of the patients in our cohort were alive, and to our knowledge, the 
survival rates at 20 years in renal AAV cohorts diagnosed after 1995 have not been reported 
elsewhere. The main potential reasons for improved patient survival are shorter diagnostic delay 
and lower cumulative CYC doses [144]. Both these facts were observed in our cohort. The 
superior survival as compared to the Finnish multicentre study could be due to the improved 
routine developed in a larger centre treating many patients with this rare disease annually. The 
latest recommendations regarding the management of AAV by EULAR and ERA-EDTA 
emphasise that AAV patients should be managed at or in close collaboration with centres of 
expertise [108]. 
As anticipated, older age is the most commonly reported factor contributing to higher 
mortality [21, 145, 147], and we confirmed this result (Study I). We also found that MPO-
ANCA-positive patients had a lower survival rate than PR3-ANCA-positive patients. The 
mortality risk for MPO-positive patients was twice as high as in PR3-ANCA-positive patients. 
However, the statistical difference (HR 2.12, 95% CI 1.08–4.17) supplied by multivariate 
analysis was hampered by the large confidence interval. Previous studies have not clearly 
confirmed this association. However, in a cluster analysis of 673 patients, a nearly 6-fold 
increase in mortality was found in renal patients without PR3-ANCA, as compared with patients 
with PR3-ANCA [154]. 
 
6.2. Renal survival 
 
Patients with MPO-ANCA had worse renal outcome than PR3-ANCA-positive patients (Study 
I). Even though it is not consistent, this association has been confirmed in many recent cohorts 
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[148, 152, 204]. In line with a recent Norwegian study, we found that males were more prone to 
developing ESRD [152]. This relationship is not widely recognised among AAV patients, but in 
CKD cohorts, the prevalence of renal replacement therapy is usually higher among men, 
specifically 1.6-fold higher according to the latest European registry data [205]. We confirmed 
the anticipated association between lower baseline renal function and the risk of ESRD [1, 149, 
158, 160, 162-164].   
Indeed, in diseases affecting the kidneys, avoiding dialysis is the main goal. Rapidly 
progressing GN is frequently seen in AAV and can lead to renal failure requiring dialysis within 
a short time. In Study I, 39%, and in Study IV, 29% of those who needed dialysis within a short 
time period after diagnosis regained renal function and were able to discontinue dialysis. After 
five years, renal survival was 79%. This result is in accordance with recent data from renal AAV 
cohorts reporting a 5-year renal survival of 77–66% [149, 156, 157]. Overall, the 20-year renal 
survival rate in Study I was 68%. 
Since the introduction of the AAV renal histology classification system, many groups 
have validated the schema of dividing renal histology into focal, crescentic, mixed and sclerotic 
subclasses. The composition of classes has been variable, but one common finding is reported: 
renal survival is best in the focal class [1, 149, 156-165]. This underscores the importance of 
early diagnosis. Renal survival has been lowest in the sclerotic class [1, 156-158, 160, 161, 163, 
164], while a few studies have found the lowest survival rate (or equal to that of the sclerotic 
group) in the crescentic class [149, 159, 165]. In Study I, renal survival was significantly better 
in the focal (88%) and in the crescentic (71%) classes than in the sclerotic class (37%). 





Relapse is a major concern in patients with AAV. As described above, the survival rate of these 
patients has improved, which in turn has allowed more relapses to occur. We found (Study I) a 
relapse-free survival rate of 47% at 5 years, which is in agreement with prior studies showing 
relapse rates of 34–49% [98, 146, 166-169]. Recently, the long-term follow-up of the WEGENT 
trial reported a 30% relapse-free survival rate at 10 years, which is comparable to our findings 
[150]. At 20 years, the relapse-free survival rate in our cohort was only 10%. Data concerning 
follow-up for that long a period are not available for comparison purposes in recent literature. 
According to our findings, the clear majority of renal patients suffer from a relapse in the long 
run. Previously, advanced renal insufficiency has been shown to be related to lower relapse risk 
[168, 169]. We could not confirm this; however, we found a trend toward lower relapse risk in 
patients with baseline GFR < 30 ml/min. This could be due to patients remaining on dialysis, 
during which no new renal relapses could occur.  
PR3-ANCA-positivity is the most commonly indicated risk factor for relapse in AAV 
[4, 98, 145, 150, 166-169]. In Study I, we also found a similar trend, but the difference was 
significant only between the diagnostic subgroups; specifically, there were fewer relapses in 
MPA. However, in Study III, the risk of relapse was higher in PR3-ANCA-positive patients than 
PR3-ANCA-negative patients (that is, MPO-ANCA-positive and ANCA-negative patients 
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pooled together), and the magnitude of this risk was higher based on ANCA-specificity as 
compared to the diagnostic subgrouping (GPA vs MPA, including patients with renal-limited 
disease). 
  
6.4. Role of S. aureus in relapse 
 
The aetiological role of S. aureus as a disease trigger in AAV has been proposed, and up to 72% 
of GPA patients have been found to be chronic carriers of SA in their noses [4, 51, 52]. 
Recently, however, a lower rate of CNSAC of 20–28% was reported in Norwegian GPA 
patients during RTX treatment [55]. In Study II, we found an even lower number, i.e., 15% of 
CNSAC in AAV patients (who were not treated with T/S). We also found that CNSAC was 
nearly exclusively observed in GPA patients, who had a CNSAC rate of 19%, which is 
comparable to that in the general population [53, 54]. Furthermore, CNSAC was associated with 
a higher relapse rate (HR 4.1) in generalised GPA, and the trend toward a higher relapse rate 
was also seen in patients with early systemic GPA who were using immunosuppressive 
medication. This finding is in line with the seminal study of Stegeman et al., which reported a 
seven-fold increase in the risk of relapse in outpatient clinic GPA patients with CNSAC [4], 
even though the magnitude of the risk we reported is closer to the later report of Zyzinska et al., 
who found a 4.5-fold increase in risk in cases of limited GPA [51]. We also found that CNSAC 
was strongly associated with S. aureus positivity at entry (OR 6.90). To define chronic carriage 
in our study, at least four swabs were required with an S. aureus positivity of at least 75%. 
Instead of performing multiple nasal swabs to confirm the carriage state, two nasal cultures 
within one week, combining both qualitative and quantitative tests, can predict persistent S. 
aureus carriage in healthy volunteers [206]. Applying this method of assessing carriage would 
facilitate the process of identifying this specific subgroup of GPA patients who are at higher risk 
of relapse. 
However, the association between chronic S. aureus carriage and increased relapse 
risk does not necessarily imply causality. Indeed, there is no evidence of a direct role on the part 
of S. aureus in AAV disease activity, even though the mechanisms that contribute to S. aureus 
colonisation and eventually lead to the outbreak of disease have been brought to light during the 
last decade [56, 57, 60]. It could also be postulated that both CNSAC and higher relapse risk are 
consequences of the same underlying factor, which could be genetically determined. Despite the 
perspective, patients with CNSAC are the subgroup of GPA patients more prone to relapse 
(Study II). Defining the S. aureus nasal carrier status in the early phases of disease could be 
valuable when considering the length of maintenance treatment in GPA patients.  
 
6.5. Role of ANCA levels in relapse 
 
The predictive value of sequential ANCA determinations in relation to relapse has been one of 
the most discussed subjects within the AAV community. In Study III, this issue was addressed 
in PR3-ANCA-positive patients with early systemic GPA via monthly measurements of PR3-
ANCA with nine ELISAs during an 18-month clinical trial. By using a new method of defining 
the peak value for PR3-ANCA, we were able to confirm that PR3-ANCA increase was closely 
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related to relapse [11]. Even though all assays identified the median peak value being higher in 
relapsing than in non-relapsing patients, the comparison was statistically different in only 2/9 
assays, and the large overlap of PR3-ANCA values between relapsing and non-relapsing 
patients made the recognition of relapse impossible. Furthermore, the largest monthly increment 
in PR3-ANCA was not able to predict relapse, and the increment in PR3-ANCA a month before 
relapse or peak (in non-relapsing patients) did not differ between the two groups, either. 
Moreover, the monthly monitoring of PR3-ANCA during the clinical trial clearly showed that 
these values are influenced by the modification of immunosuppressive medications. Thus, the 
findings of Study III are largely consistent with those of a meta-analysis concluding that serial 
ANCA monitoring was of limited use in predicting future relapse [136]. 
Recent data on the effect of disease state and treatment on ANCA responses in 
relation to relapse could offer further explanations for the observations in Study III. In patients 
with severe disease (that is, renal involvement or alveolar haemorrhage), ANCA increase seems 
to correlate with relapses to a greater degree than in patients with milder AAV [140, 141]. As 
described above, the patients in Study III had early systemic AAV, and severe disease was an 
exclusion criterion. Likewise, the therapeutic regimen seems to contribute to ANCA responses: 
after RTX induction, an increase in PR3-ANCA was associated with increased relapse, whereas 
in CYC/AZA-treated patients, such an association was not observed [141]. The patients in Study 
III were treated with either CYC or MTX in addition to GC.  
 
6.6. Coagulation and fibrinolysis activity  
   
The increased risk of VTE among AAV patients is well-established, and the risk is highest 
during the active phase of the disease [6, 173-177]. This was confirmed in Study IV, in which 
9.5% of AAV patients developed VTE within four months of diagnosis.  
In general, we observed that patients with active AAV present a state of enhanced 
coagulation and fibrinolysis (Study IV). In particular, thrombin formation (measured with F1+2) 
and fibrin degradation (measured with D-dimer) were predominating during the acute phase of 
the disease. This is in agreement with the earlier observations showing elevated D-dimer levels 
during active AAV [181, 207]. Interestingly, D-dimer levels were correlated with BVAS (Study 
IV), suggesting that the activation of coagulation and fibrinolysis is linked with multi-organ 
AAV. Both F1+2 and D-dimer levels showed the potential to differentiate between patients with 
mild disease and those with more complicated disease. Furthermore, both F1+2 and D-dimer 
levels were negatively correlated with GFR during the acute phase of the disease, referring to 
the pathogenic process of active necrotising glomerulonephritis, and also to the enhanced 
thrombin formation and fibrin degradation in patients with advanced kidney disease.   
High levels of FVIII, VWF:RCo and VWF:Ag were found during both the active and 
remission phase of AAV (Study IV). Previously, elevated levels of VWF were found regardless 
of disease state, and more recently, high levels of FVIII were detected during stable remission 
[181, 190]. Both earlier observations were derived from AAV cohorts excluding patients with 
advanced renal impairment, and the Dutch cohort comprised mainly GPA patients. High levels 
of VWF and FVIII could reflect ongoing endothelial involvement during the remission phase of 
the disease. In Study VI, D-dimer levels remained above the normal reference values in half of 
the patients in whom remission was achieved, whereas in another study, D-dimer levels during 
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remission were comparable to those of healthy controls [190]. This difference could be 
explained by the timepoints of the measurement: in Study IV, D-dimer was measured at a 
median of 6 months from diagnosis, whereas in another study, the patients had quiescent AAV 
that had been diagnosed 6 years earlier. Thus, D-dimer might represent a marker of disease 
activity in AAV. 
To examine the association between renal function and coagulation activity and 
fibrinolysis, the AAV patients in Study IV were compared with patients with other renal 
diseases, who were divided into two groups based on kidney function. In general, the cumulative 
load of coagulopathies (defined as the sum of coagulation variables) was clearly lower in 
patients with mild renal impairment than in patients with AAV, regardless of disease state, 
whereas in patients with more advanced renal disease, the coagulopathy load was different only 
in comparison with active AAV. This suggests that AAV patients with renal disease could be a 
special group regarding the risk of thrombotic events. In fact, this assumption was recently 
shown to be true: the risk of VTE was increased in AAV patients with higher baseline creatinine 
levels [176]. 
The increased risk of VTE is recognised in the treatment guidelines for AAV. 
However, no controlled trials have been conducted, and there is an overall lack of knowledge of 
the potential benefits and risks of anticoagulation in AAV patients. Such data are needed, not 
only to reduce VTE comorbidity but also to address the question of whether anticoagulation 
therapy could affect renal function and improve renal survival in AAV patients.   
 
6.7. Strengths and limitations 
 
The main strength of Study I was the long follow-up; outcome data spanning 20 years are 
exceptional in the AAV literature. In addition, all patients were followed from the diagnosis of 
the disease. The retrospective nature and the rather small number of patients were the main 
limitations of Study I. Also, the cohort is historical. It included patients who were diagnosed 
between 1996 and 2005 and primarily given CYC and GC as an induction treatment and AZA 
with GC as a maintenance treatment. In addition, the fact that Study I included only patients in 
whom a renal biopsy had been performed may bias the results. The oldest and most severely ill 
patients likely never underwent renal biopsy, due to their condition or premises of being treated 
with potentially toxic medication. Likewise, not all AAV patients with minor signs of renal 
disease may have undergone renal biopsy, either. Thus, the conclusions from Study I may be 
less valid regarding the aforementioned patients. In addition, the retrospective set-up of Study I 
permits the possibility that minor recurrent disease activity was never recorded and the data on 
relapses were thus underestimated. Furthermore, we only analysed the effect of baseline 
parameters on survival. However, the disease course is a dynamic process, and the longer the 
follow-up, the more factors may interfere with the endpoints. 
The strength of Study II was the combination of two AAV cohorts comprised of 
patients in various disease states. Furthermore, the S. aureus nasal cultures were obtained at 
short intervals. Even though the planned monthly collection of nasal swaps was not feasible in 
every patient, the median number of S. aureus nasal cultures per patient was 12. Hence, the 
number of swaps enabled the reliable segregation of patients into different nasal carrier status 
subgroups. The limitation of Study II was that the potential use of antibiotics prior to AAV 
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diagnosis, which is quite common among AAV patients presenting with flu-like symptoms, was 
not recorded, and this may have had an impact on the frequency of CNSAC. Furthermore, for 
the diagnosis of an ENT relapse (which constituted 48% of all relapses), a biopsy was not 
required, and the clinical separation of nasal infection from nasal AAV activity may be difficult. 
The strength of Study III was the use of a novel method of defining peak value for 
PR3-ANCA, which permitted the identification and comparison of the highest PR3-ANCA 
values for both relapsing and non-relapsing patients. In addition, the monthly ANCA 
measurements obtained during the RCT under a pre-scheduled and controlled treatment scheme 
made it possible to observe the effects of medication on PR3-ANCA levels. However, even 
though the peak value could identify relapse in practically all relapsing patients, the usefulness 
of that method is limited in a real clinical context because the peak can only be defined 
retrospectively. The limitation of Study III is the small number of patients, which was due to the 
lack of sufficient amount of sera collected according to the protocol. In addition, the study 
population had early systemic GPA without overt renal disease, and the results may be less valid 
for a more severe disease.  
The strength of Study IV was that it included a wide range of renal AAV patients in 
various disease states, although the total number of AAV patients was limited. The use of 
control groups with other renal diseases made it possible to examine the effect of renal 
impairment on coagulation activity. Even though the group of AAV patients in Study IV was 
heterogeneous, with factors and complications interfering with the delicate system of 
















The conclusions of the present series of studies are as follows: 
 
1. In the long-term follow-up of renal AAV patients, improved patient and renal 
survival were confirmed. Moreover, survival data for up to 20 years could be 
presented. Both patient and renal survival were negatively predicted by MPO-
ANCA. ESRD was more common in men. As anticipated, younger age was 
associated with favourable patient survival and better renal function at baseline, as 
well as with better renal survival. The risk of ESRD was the lowest in patients with 
focal AAGN and the highest in patients with sclerotic AAGN. The relapse risk 
proved to be high in this renal cohort, and patients with GPA were more prone to 
relapse than MPA patients. (Study I) 
 
2. Among patients with AAV, the frequency of CNSAC was lower than that reported 
previously. In GPA patients, however, CNSAC was higher than in non-GPA 
patients and comparable to the general population. In patients with generalised 
GPA, CNSAC was associated with relapse, and in patients with early systemic 
GPA using immunosuppressive treatment, a similar trend for this association was 
found. Thus, patients with CNSAC represent a GPA subgroup with an increased 
risk of relapse. (Study II) 
 
3. In patients with early systemic GPA, the PR3-ANCA peak coincided with relapse. 
In non-relapsing patients, such a peak in PR3-ANCA could also be identified, 
reflecting the tapering of the immunosuppressive medication. Thus, PR3-ANCA 
levels were reflected not only by the disease activity but also by the level of 
immunosuppressive medication. The large overlaps in PR3-ANCA values at 
relapse or peak (in non-relapsing patients) made it difficult to differentiate 
relapsing patients from non-relapsing patients. (Study III) 
 
4. Patients with active renal AAV exhibited a state of enhanced coagulation and 
fibrinolysis. During remission, thrombin formation and fibrin turnover were largely 
reduced, whereas FVIII activity remained high, indicating ongoing endothelial 
involvement. Markers of coagulation and fibrinolysis were comparable between 
AAV patients in remission and other renal patients with at least moderate renal 
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